CN1352252A - New polypeptide-human II aminoacyl-tRNA synthetase 11.77 and polynucleotide for encoding such polypeptide - Google Patents
New polypeptide-human II aminoacyl-tRNA synthetase 11.77 and polynucleotide for encoding such polypeptide Download PDFInfo
- Publication number
- CN1352252A CN1352252A CN 00127268 CN00127268A CN1352252A CN 1352252 A CN1352252 A CN 1352252A CN 00127268 CN00127268 CN 00127268 CN 00127268 A CN00127268 A CN 00127268A CN 1352252 A CN1352252 A CN 1352252A
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- polynucleotide
- aminoacyl
- human
- trna synthetase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Abstract
The present invention discloses a new kind of polypeptide, human II aminoacyl-tRNA synthetase 11.77, polynucleotides for encoding this polypeptide and DNA recombination process to produce the polypeptide. The present invention also discloses the method of applying the polypeptide in treating various diseases, such as malignant tumors, hemopathy, HIV infection, immunological diseases and various inflammations. The persent invention also discloses the antagonist resisting the polypeptide and its treatment effect. The present invention also discloses the application of the polynucleotides for encoding human II aminoacyl-tRNA synthetase 11.77.
Description
The invention belongs to biological technical field, specifically, the invention describes a kind of new polypeptide-human II aminoacyl-tRNA synthetase 11 .77, and the polynucleotide sequence of this polypeptide of encoding.The invention still further relates to the preparation method and the application of these polynucleotide and polypeptide.
In the translation process of mRNA, tRNA plays the function that the codon of mRNA and corresponding amino acid are mapped.There is no structural dependency between anticodon on the tRNA molecule amino acid corresponding with it; and tRNA itself can not the corresponding amino acid whose load of catalysis, is catalytic by aminoacyl-tRNA synthetase with tRNA with the reaction that corresponding amino acid combines.
The reaction of the synthetic aminoacyl-tRNA of aminoacyl tRNA synthetase was divided into for two steps: amino acid at first activates into aminoacyl adenylate, and afterwards, aminoacyl adenylate generates aminoacyl-tRNA with tRNA again.Aminoacyl-tRNA synthetase is discerned different tRNA by " paracodon " on the tRNA molecule, so that correct amino acid and tRNA are combined.
Each amino acid all corresponding a kind of aminoacyl-tRNA synthetase, therefore, 20 seed amino acids just have 20 kinds of different aminoacyl-tRNA synthetases.But these 20 kinds of aminoacyl-tRNA synthetases are related each other.Different according to structure and sequence, 20 kinds of aminoacyl-tRNA synthetases can be divided into two classes, I class and II class.I zymoid catalysed partial contains the folding skeleton that constitutes of Rossmann, and this is a kind of nucleic acid calmodulin binding domain CaM; II zymoid skeleton then is made of a kind of new antiparallel folding.The sequence homology degree of II aminoacyl-tRNA synthetic enzyme is not high; but at least two conservative zones are all arranged: [FYH]-R-x-[DE]-x (4,12)-[RH]-x (3)-F-x (3)-[DE] [GSTALVF]-DENQHRKP-[GSTA]-[LIVMF]-[DE]-R-[LIVMF]-x-[LIVMSTAG]-[LIVMFY]
Aminoacyl-tRNA synthetase provides the available aminoacyl-tRNA of synthetic protein.If certain aminoacyl-tRNA synthetase disappearance can cause corresponding aminoacyl-tRNA correctly not form, cause the early stopping of crossing of synthetic protein process, form the albumen that does not have function.If certain aminoacyl-tRNA synthetase is undergone mutation; discern another kind of amino acid; then the protein of Xing Chenging comprises incorrect aminoacid sequence; if this variation occurs on the amino acid sites crucial concerning this proteinic function; the protein of Xing Chenging can not correctly fold and not have function so; perhaps miopragia or enhancing perhaps changed the substrate of effect and its function changed.Variation on this function usually causes disease.
For example, in people's tumour of 25%-30%, the Ras albumen that notes abnormalities, in 12 point mutation that obtain 61 residues of Ras, glycine has replaced Xie Ansuan again, the activity that suppresses the GTP enzyme of Ras itself and GAP stimulation, therefore can not be that Ras-GTP is transformed into Ras-GDP, cause Ras to be in active condition for a long time, the signal of granting downstream that does not stop, cause the abnormality proliferation of cell, thereby cause the generation of cancer.The letter sorting of probable protein and the malfunction of parasecretion and membrane receptor etc. are gone back in the sudden change of aminoacyl-tRNA synthetase, cause various endocrinopathys, disease of immune system, neuromuscular system disease etc.Protein of the present invention contains the characteristic conservative region of II aminoacyl-tRNA synthetic enzyme; and; find by analysis express spectra; II aminoacyl-tRNA synthetase expression level in the normal liver tissue is than the expression amount height in the liver cancer tissue, in normal larynx tissue and laryngeal carcinoma tissue identical discovery arranged also.In sum, think that polypeptide of the present invention is a kind of new II aminoacyl-tRNA synthetic enzyme, have similar biological function, and called after human II aminoacyl-tRNA synthetase 11 .11.
Analysis by gene chip is found; at normal brain activity, liver cancer, muscle, tire brain, tire kidney; in tire lung, tire liver, Tiroidina, thymus gland, adult liver, lung, the glioma; polypeptide expression spectrum of the present invention is very approximate with the express spectra of human II aminoacyl-tRNA synthetic enzyme, so the two function also may be similar.The present invention is named as human II aminoacyl-tRNA synthetase 11 .77.
Because human II aminoacyl-tRNA synthetase 11 .77 albumen plays an important role in regulating body critical functions such as cell fission and fetal development as mentioned above; and believe and relate to a large amount of albumen in these regulate processes; thereby need to identify the human II aminoacyl-tRNA synthetase 11 .77 albumen of more these processes of participation in this area always, particularly identify this proteic aminoacid sequence.The separation of new human II aminoacyl-tRNA synthetase 11 .77 protein coding gene also provides the foundation for determining the effect of this albumen under healthy and morbid state.This albumen may constitute the basis of 1 sick diagnosis of exploitation disease and/or curative, and it is very important therefore separating its coding DNA.
An object of the present invention is to provide isolating new polypeptide-human II aminoacyl-tRNA synthetase 11 .77 with and fragment, analogue and derivative.
Another object of the present invention provides the polynucleotide of this polypeptide of coding.
Another object of the present invention provides the recombinant vectors of the polynucleotide that contain coding human II aminoacyl-tRNA synthetase 11 .77.
Another object of the present invention provides the genetically engineered host cell of the polynucleotide that contain coding human II aminoacyl-tRNA synthetase 11 .77.
Another object of the present invention provides the method for production human II aminoacyl-tRNA synthetase 11 .77.
Another object of the present invention provides the antibody at polypeptide-human II aminoacyl of the present invention-tRNA synthetase 11 .77.
Another object of the present invention has provided simulated compound, antagonist, agonist, the inhibitor at polypeptide-human II aminoacyl of the present invention-tRNA synthetase 11 .77.
Another object of the present invention provides the method for the diagnoses and treatment disease relevant unusually with human II aminoacyl-tRNA synthetase 11 .77.
The present invention relates to a kind of isolated polypeptide, this polypeptide is the people source, and it comprises: polypeptide or its examples of conservative variations, bioactive fragment or derivative with SEQ ID No.2 aminoacid sequence.Preferably, this polypeptide is the polypeptide with SEQ ID NO:2 aminoacid sequence.
The invention still further relates to a kind of isolating polynucleotide, it comprises a kind of nucleotide sequence or its variant that is selected from down group:
(a) coding has the polynucleotide of the polypeptide of SEQ ID No.2 aminoacid sequence;
(b) with polynucleotide (a) complementary polynucleotide;
(c) with (a) or polynucleotide sequence (b) have the polynucleotide of at least 70% homogeny.
More preferably, the sequence of these polynucleotide is be selected from down group a kind of: the sequence that (a) has 1070-2543 position among the SEQ ID NO:1; (b) has the sequence of 1-2822 position among the SEQ ID NO:1.
The present invention relates to a kind of carrier that contains polynucleotide of the present invention, particularly expression vector in addition; The host cell that this carrier of a kind of usefulness is genetically engineered comprises the host cell of conversion, transduction or transfection; A kind of method for preparing polypeptide of the present invention of cultivating described host cell and reclaiming expression product that comprises.
The invention still further relates to a kind of can with polypeptid specificity bonded antibody of the present invention.
The invention still further relates to a kind of simulation, activation, antagonism of screening or suppress the method for the compound of human II aminoacyl-tRNA synthetase 11 .77 protein-active, it comprises and utilizes polypeptide of the present invention.The invention still further relates to the compound that obtains with this method.
The invention still further relates to a kind of vitro detection and express the relevant disease or the method for disease susceptibility with human II aminoacyl-tRNA synthetase 11 .77 abnormal protein; comprise the sudden change in polypeptide described in the detection of biological sample or its coded polynucleotide sequence, perhaps the amount or the biological activity of polypeptide of the present invention in the detection of biological sample.
The present invention also relates to a kind of pharmaceutical composition, it contains polypeptide of the present invention or its stand-in, activator, antagonist or inhibitor and pharmaceutically acceptable carrier.
The invention still further relates to polypeptide of the present invention and/or polynucleotide and be used for the treatment of cancer, developmental character disease or immunological disease or other purposes owing to the medicine of human II aminoacyl-tRNA synthetase 11 .77 disease that abnormal expression causes in preparation.
Others of the present invention are because disclosing of the technology of this paper is conspicuous to those skilled in the art.
The following term of using in this specification sheets and claims has following implication unless stated otherwise:
" nucleotide sequence " is meant oligonucleotide, Nucleotide or polynucleotide and fragment or part, also can refer to genome or synthetic DNA or RNA, and they can be strand or two strands, represent sense strand or antisense strand.Similarly, term " aminoacid sequence " is meant oligopeptides, peptide, polypeptide or protein sequence and fragment or part.When " aminoacid sequence " among the present invention related to a kind of aminoacid sequence of naturally occurring protein molecule, this " polypeptide " or " protein " did not mean that aminoacid sequence are restricted to the complete natural amino acid relevant with described protein molecule.
Protein or polynucleotide " variant " are meant a kind of polynucleotide sequence that has the aminoacid sequence of one or more amino acid or Nucleotide change or encode it.Described change can comprise disappearance, insertion or the replacement of amino acid in aminoacid sequence or the nucleotide sequence or Nucleotide.Variant can have " conservative property " and change, and wherein the amino acid of Ti Huaning has structure or the chemical property similar with original acid, as replacing Isoleucine with leucine.Variant also can have non-conservation and change, as replacing glycine with tryptophane.
" disappearance " is meant the disappearance of in aminoacid sequence or nucleotide sequence one or more amino acid or Nucleotide.
" insertion " or " interpolation " is meant that the change in aminoacid sequence or nucleotide sequence causes comparing the increase of one or more amino acid or Nucleotide with naturally occurring molecule." replacement " is meant by different amino acid or Nucleotide and replaces one or more amino acid or Nucleotide.
" biological activity " is meant the protein of structure, regulation and control or biochemical function with natural molecule.Similarly, term " immunologic competence " be meant natural, reorganization or synthetic protein and fragment thereof in suitable animal or cell, induce specific immune response and with specific antibody bonded ability.
" agonist " be meant when with human II aminoacyl-when tRNA synthetase 11 .77 combines, thereby a kind of this protein that causes changes the molecule of regulating this protein active.Agonist can comprise protein, nucleic acid, carbohydrate or any other can be in conjunction with the molecule of human II aminoacyl-tRNA synthetase 11 .77.
" antagonist " or " inhibition " be meant when with human II aminoacyl-when tRNA synthetase 11 .77 combines, a kind ofly seal or regulate the human II aminoacyl-biologic activity of tRNA synthetase 11 .77 or the molecule of immunologic competence.Antagonist and inhibition can comprise protein, nucleic acid, carbohydrate or any other can be in conjunction with the molecule of human II aminoacyl-tRNA synthetase 11 .77.
" adjusting " is meant that the function of human II aminoacyl-tRNA synthetase 11 .77 changes, and comprises the change of any other biological property, function or the immune property of the change of the rising of protein active or reduction, binding characteristic and human II aminoacyl-tRNA synthetase 11 .77.
The pure basically ＂ of ＂ is meant and is substantially free of natural relative other albumen, lipid, carbohydrate or other material.Those skilled in the art can use the purified technology of protein purifying human II aminoacyl-tRNA synthetase 11 .77 of standard.Basically pure human II aminoacyl-tRNA synthetase 11 .77 can produce single master tape on the irreducibility polyacrylamide gel.The purity available amino end acid sequence of human II aminoacyl-tRNA synthetase 11 .77 polypeptide is analyzed.
" complementary " or " complementation " is meant under salt concn that allows and temperature condition by the natural combination of the polynucleotide of base pairing.For example, sequence " C-T-G-A " can combine with complementary sequence " G-A-C-T ".Complementation between two single chain molecules can be part or whole.Complementary degree between the nucleic acid chains has a significant effect for efficient of hybridizing between the nucleic acid chains and intensity.
" homology " is meant the complementary degree, can be portion homologous or complete homology." portion homologous " is meant a kind of part complementary sequence, and it can partly suppress the hybridization of complete complementary sequence and target nucleic acid at least.The inhibition of this hybridization can detect by hybridizing (Southern trace or Northern trace etc.) under the condition that reduces in the severity degree.Basically homologous sequence or hybridization probe can compete and suppress complete homologous sequence and target sequence the condition that reduces of severity degree under combine.This does not mean the conditions permit non-specific binding that the severity degree reduces because the conditional request two sequences that the severity degree reduces mutual be combined into specificity or selectivity interacts.
" homogeny percentage " be meant two or more amino acid or nucleotide sequence relatively in the same or analogous percentage of sequence.The available electron method is measured the homogeny percentage, as passing through MEGALIGN program (Lasergenesoftware package, DNASTAR, Inc., Madison Wis.).The MEGALIGN program can compare two or more sequences (Higgins, D.G. and P.M.Sharp (1988) Gene 73:237-244) according to diverse ways such as Cluster method.The Cluster method is organized the series arrangement cluster by checking the distance between all pairings with each.Then with each bunch with in pairs or become set of dispense.Homogeny percentage between two aminoacid sequences such as sequence A and the sequence B calculates by following formula:
Also can be by the Cluster method or with the homogeny percentage (Hein J., (1990) Methods in emzumology 183:625-645) between known method in this area such as the Jotun Hein mensuration nucleotide sequence.
" similarity " is meant the degree that the identical or conservative property of corresponding position amino-acid residue when arranging contrast between the aminoacid sequence replaces.For example be used for amino acid that conservative property replaces, electronegative amino acid can comprise aspartic acid and L-glutamic acid; Positively charged amino acid can comprise Methionin and arginine; Having uncharged head group has similar hydrophilic amino acid can comprise leucine, Isoleucine and Xie Ansuan; Glycine and L-Ala; L-asparagine and glutamine; Serine and Threonine; Phenylalanine and tyrosine.
" antisense " is meant and specific DNA or RNA sequence complementary nucleotide sequence." antisense strand " is meant and " sense strand " complementary nucleic acid chains.
" derivative " is meant HFP or encodes its chemical modification object of nucleic acid.This chemical modification object can be with alkyl, acyl group or the amino hydrogen atom of replacing.The nucleic acid derivative codified keeps the polypeptide of the main biological characteristics of natural molecule.
" antibody " is meant complete antibody molecule and fragment thereof, as Fa, F (ab ')
2And Fv, its energy specificity is in conjunction with the antigenic determinant of human II aminoacyl-tRNA synthetase 11 .77.
" humanized antibody " is meant that the aminoacid sequence in non-antigen binding domain territory is replaced and becomes more similar to people's antibody, but still keep original in active antibody.
" isolating " speech refers to material is shifted out among its original environment (for example, if spontaneous its natural surroundings that just refers to).Such as it is exactly not to be separated that spontaneous polynucleotide or polypeptide are present in the Live Animals, but same polynucleotide or polypeptide with some or all in natural system with it the material of coexistence separately be exactly isolating.Such polynucleotide may be the parts of a certain carrier, the part that also possible such polynucleotide or polypeptide are a certain composition.Since carrier or composition are not the compositions of its natural surroundings, they remain isolating.
As used herein, " isolating " are meant that material separates (if natural substance, primal environment promptly is a natural surroundings) from its primal environment.Do not have separation and purification as polynucleotide under the native state in the active somatic cell and polypeptide, but same polynucleotide or polypeptide as from native state with in other materials that exist separately, then for separation and purification.
As used herein, " isolating human II aminoacyl-tRNA synthetase 11 .77 " is meant that human II aminoacyl-tRNA synthetase 11 .77 is substantially free of natural relative other albumen, lipid, carbohydrate or other material.Those skilled in the art can use the purified technology of protein purifying human II aminoacyl-tRNA synthetase 11 .77 of standard.Basically pure polypeptide can produce single master tape on non-reduced polyacrylamide gel.The purity of human II aminoacyl-tRNA synthetase 11 .77 polypeptide can be used amino acid sequence analysis.
The invention provides a kind of new polypeptide-human II aminoacyl-tRNA synthetase 11 .77, it is made up of the aminoacid sequence shown in the SEQ ID NO:2 basically.Polypeptide of the present invention can be recombinant polypeptide, natural polypeptides, synthetic polypeptide, preferred recombinant polypeptide.Polypeptide of the present invention can be the product of natural purifying, or the product of chemosynthesis, or uses recombinant technology to produce from protokaryon or eucaryon host (for example, bacterium, yeast, higher plant, insect and mammalian cell).The host used according to the recombinant production scheme, polypeptide of the present invention can be glycosylated, maybe can be nonglycosylated.Polypeptide of the present invention also can comprise or not comprise initial methionine residues.
The present invention also comprises fragment, derivative and the analogue of human II aminoacyl-tRNA synthetase 11 .77.As used herein, term " fragment ", " derivative " are meant with " analogue " and keep identical biological function of human II aminoacyl of the present invention-tRNA synthetase 11 .77 or active polypeptide basically.The fragment of polypeptide of the present invention, derivative or analogue can be: (I) a kind of like this, wherein one or more amino-acid residues are replaced by conservative or non-conservative amino acid residues (preferably conservative amino acid residues), and the amino acid that replaces can be also can not encoded by genetic codon; Perhaps (II) is a kind of like this, and certain group on wherein one or more amino-acid residues is replaced by other group and comprises substituting group; Perhaps (III) is a kind of like this, and wherein mature polypeptide and another kind of compound (such as the compound that prolongs the polypeptide transformation period, for example polyoxyethylene glycol) merge; Perhaps (IV) is a kind of like this, wherein additional aminoacid sequence is integrated into mature polypeptide and the peptide sequence that forms (as leader sequence or secretion sequence or be used for the sequence or the proteinogen sequence of this polypeptide of purifying) by the elaboration of this paper, such fragment, 00 derivative and analogue are considered within those skilled in the art's ken.
The invention provides isolating nucleic acid (polynucleotide), substantially the polynucleotide that have a polypeptide of SEQ ID NO:2 aminoacid sequence by coding are formed.Polynucleotide sequence of the present invention comprises the nucleotide sequence of SEQ ID NO:1.Polynucleotide of the present invention are to find from the cDNA library of people's fetal brain tissue.The polynucleotide sequence total length that it comprises is 2822 bases, its open reading frame 1070-2543 107 amino acid of having encoded.Find relatively that according to gene chip expression spectral this polypeptide has similar express spectra to human II aminoacyl-tRNA synthetic enzyme, deducibility goes out this human II aminoacyl-tRNA synthetase 11 .77 and has human II aminoacyl-similar function of tRNA synthetic enzyme.
Polynucleotide of the present invention can be dna form or rna form.Dna form comprises the DNA of cDNA, genomic dna or synthetic.DNA can be strand or double-stranded.DNA can be coding strand or noncoding strand.The coding region sequence of encoding mature polypeptide can be identical with the coding region sequence shown in the SEQ ID NO:1 or the varient of degeneracy.As used herein, " varient of degeneracy " are meant that in the present invention coding has protein or the polypeptide of SEQ ID NO:2, but with the differentiated nucleotide sequence of coding region sequence shown in the SEQ ID NO:1.
The polynucleotide of the mature polypeptide of coding SEQ ID NO:2 comprise: the encoding sequence that has only mature polypeptide; The encoding sequence of mature polypeptide and various additional code sequence; Encoding sequence of mature polypeptide (with optional additional code sequence) and non-coding sequence.
Term " polynucleotide of coded polypeptide " is meant polynucleotide that comprise this polypeptide of encoding and the polynucleotide that comprise additional code and/or non-coding sequence.
The invention still further relates to the varient of foregoing description polynucleotide, its coding has the polypeptide of identical aminoacid sequence or segment, analogue and the derivative of polypeptide with the present invention.The varient of these polynucleotide can be the allelic variant of natural generation or the varient that non-natural takes place.These nucleotide diversity bodies comprise and replace varient, deletion mutation body and insert varient.As known in the art, allelic variant is the replacement form of polynucleotide, and it may be replacement, disappearance or the insertion of one or more Nucleotide, but can be from not changing the function of its encoded polypeptides in fact.
The invention still further relates to and the polynucleotide (have at least 50% between two sequences, preferably have 70% homogeny) of sequence hybridization described above.The present invention be more particularly directed under stringent condition and the interfertile polynucleotide of polynucleotide of the present invention.In the present invention, " stringent condition " is meant: (1) than hybridization under low ionic strength and the comparatively high temps and wash-out, as 0.2 * SSC, and 0.1%SDS, 60 ℃; Or (2) hybridization the time adds and to use denaturing agent, as 50% (v/v) methane amide, 0.1% calf serum/0.1%Ficoll, 42 ℃ etc.; Or (3) only at the homogeny between the two sequences at least more than 95%, be more preferably 97% and just hybridize when above.And the polypeptide of interfertile polynucleotide encoding has identical biological function and activity with the mature polypeptide shown in the SEQ ID NO:2.
The invention still further relates to nucleic acid fragment with sequence hybridization described above.As used herein, " nucleic acid fragment " length contain 10 Nucleotide at least, better be 20-30 Nucleotide at least, be more preferably 50-60 Nucleotide at least, preferably more than at least 100 Nucleotide.Nucleic acid fragment also can be used for the amplification technique (as PCR) of nucleic acid to determine and/or to separate the polynucleotide of coding human II aminoacyl-tRNA synthetase 11 .77.
Polypeptide among the present invention and polynucleotide preferably provide with isolating form, more preferably are purified to homogeneous.
The special polynucleotide sequence of coding human II aminoacyl of the present invention-tRNA synthetase 11 .77 can obtain with several different methods.For example, separate polynucleotide with hybridization technique well known in the art.These technology including, but not limited to: 1) with probe and genome or the hybridization of cDNA library to detect homologous polynucleotide sequence and 2) antibody screening of expression library to be to detect the polynucleotide passage of the clone with common structure feature.
Sequence dna fragment of the present invention also can obtain with following method: 1) separate double chain DNA sequence from genomic dna; 2) the chemical synthesising DNA sequence is to obtain the double-stranded DNA of described polypeptide.
In the above-mentioned method of mentioning, isolation of genomic DNA is least commonly used.The direct chemical of dna sequence dna is synthetic to be the method for often selecting for use.The more frequent method of selecting for use is the separation of cDNA sequence.The standard method that separates interested cDNA is from the donorcells separating mRNA of this gene of high expression level and carries out reverse transcription, forms plasmid or phage cDNA library.Extract the existing multiple proven technique of method of mRNA, test kit also can obtain (Qiagene) from commercial channels.And the construction cDNA library also is usual method (Sambrook, et al., MolecularCloning, A Laboratory Manual, Cold Spring Harbor Laboratory.New York, 1989).Also can obtain the cDNA library of commercial offers, as the different cDNA library of Clontech company.When being used in combination the polymeric enzyme reaction technology, even few expression product also can be cloned.
Available ordinary method is screened gene of the present invention from these cDNA libraries.These methods include, but is not limited to: (1) DNA-DNA or DNA-RNA hybridization; (2) appearance of marker gene function or forfeiture; (3) level of the transcript of mensuration human II aminoacyl-tRNA synthetase 11 .77; (4), detect the protein product of genetic expression by immunological technique or mensuration biologic activity.Aforesaid method can singly be used, but also several different methods combined utilization.
In (1) kind method, hybridizing used probe is and any a part of homology of polynucleotide of the present invention that at least 10 Nucleotide of its length better are at least 30 Nucleotide, are more preferably at least 50 Nucleotide, preferably at least 100 Nucleotide.In addition, within 2000 Nucleotide, preferable is within 1000 Nucleotide to the length of probe usually.Probe used herein is the dna sequence dna of chemosynthesis on the basis of gene order information of the present invention normally.Gene of the present invention itself or fragment are certainly as probe.The mark of dna probe can be used radio isotope, fluorescein or enzyme (as alkaline phosphatase) etc.
In (4) kind method, detect the protein product of human II aminoacyl-tRNA synthetase 11 .77 genetic expression and can use immunological technique such as Western blotting, radioimmunoprecipitation, enzyme-linked immunosorbent assay (ELISA) etc.
Use method (Saiki, the et al.Science1985 of round pcr DNA amplification/RNA; 230:1350-1354) be optimized for acquisition gene of the present invention.When particularly being difficult to from the library, obtain the cDNA of total length, can preferably use RACE method (the terminal rapid amplifying method of RACE-cDNA), the primer that is used for PCR can suitably be selected according to polynucleotide sequence information of the present invention disclosed herein, and available ordinary method is synthetic.Available ordinary method is as the DNA/RNA fragment by gel electrophoresis separation and purifying amplification.
The gene of the present invention that obtains as mentioned above, perhaps the polynucleotide sequence of various dna fragmentations etc. can with ordinary method such as dideoxy chain termination (Sanger et al.PNAS, 1977,74:5463-5467) measure.This class polynucleotide sequence is measured also available commercial sequencing kit etc.In order to obtain the cDNA sequence of total length, order-checking need be carried out repeatedly.Sometimes need to measure a plurality of clones' cDNA sequence, just can be spliced into the cDNA sequence of total length.
The present invention also relates to comprise the carrier of polynucleotide of the present invention; and with carrier of the present invention or directly with the host cell of human II aminoacyl-tRNA synthetase 11 .77 encoding sequence, and the method that produces polypeptide of the present invention through recombinant technology through the genetically engineered generation.
Among the present invention, the polynucleotide sequence of coding human II aminoacyl-tRNA synthetase 11 .77 can be inserted in the carrier, contains the recombinant vectors of polynucleotide of the present invention with formation.Term " carrier " refers to that bacterial plasmid well known in the art, phage, yeast plasmid, vegetable cell virus, mammalian cell virus are as adenovirus, retrovirus or other carrier.The carrier of Shi Yonging includes but not limited in the present invention: and the expression vector based on the T7 promotor of in bacterium, expressing (Rosenberg, et al.Gene, 1987,56:125); The pMSXND expression vector of in mammalian cell, expressing (Lee and Nathans, J Bio Chem.263:3521,1988) and at the carrier that derives from baculovirus of expressed in insect cells.In a word, as long as can duplicate in host and stablize, any plasmid and carrier may be used to make up recombinant expression vector.A key character of expression vector is to contain replication origin, promotor, marker gene and translational control element usually.
Method well-known to those having ordinary skill in the art can be used to make up the dna sequence dna that contains coding human II aminoacyl-tRNA synthetase 11 .77 and the expression vector of suitable transcribing/translational control element.These methods comprise (Sambroook, et al.MolecularCloning, a Laboratory Manual, cold Spring Harbor Laboratory.New York, 1989) such as extracorporeal recombinant DNA technology, DNA synthetic technology, the interior recombinant technologys of body.Described dna sequence dna can effectively be connected on the suitable promotor in the expression vector, and is synthetic to instruct mRNA.The representative example of these promotors has: colibacillary lac or trp promotor; The P of lambda particles phage
LPromotor; Eukaryotic promoter comprises LTRs and some other known may command gene expression promoter in prokaryotic cell prokaryocyte or eukaryotic cell or its virus of CMV immediate early promoter, HSV thymidine kinase promoter, early stage and late period SV40 promotor, retrovirus.Expression vector also comprises ribosome bind site that translation initiation is used and transcription terminator etc.Inserting enhancer sequence in carrier will make its transcribing in higher eucaryotic cells be enhanced.Enhanser is the cis acting factor that DNA expresses, and nearly 10 to 300 base pairs act on promotor transcribing with enhancing gene usually.Can for example be included in the SV40 enhanser of 100 to 270 base pairs of replication origin side in late period one, at the polyoma enhanser of replication origin side in late period one and adenovirus enhanser etc.
In addition, expression vector preferably comprises one or more selected markers, to be provided for selecting the phenotypic character of transformed host cells, cultivate Tetrahydrofolate dehydrogenase, neomycin resistance and the green fluorescent protein (GFP) of usefulness as eukaryotic cell, or be used for colibacillary tsiklomitsin or amicillin resistance etc.
Persons skilled in the art all know how to select appropriate carriers/transcriptional regulatory element (as promotor, enhanser etc.) and selected marker.
Among the present invention, the polynucleotide of coding human II aminoacyl-tRNA synthetase 11 .77 or the recombinant vectors that contains these polynucleotide can transform or transduce into host cell, contain the genetically engineered host cell of these polynucleotide or recombinant vectors with formation.Term " host cell " refers to prokaryotic cell prokaryocyte, as bacterial cell; Or eukaryotic cell such as low, as yeast cell; Or higher eucaryotic cells, as mammalian cell.Representative example has: intestinal bacteria, streptomyces; Bacterial cell such as Salmonella typhimurium; Fungal cell such as yeast; Vegetable cell; Insect cell such as fruit bat S2 or Sf9; Zooblast such as CHO, COS or Bowes melanoma cells etc.
Can carry out with routine techniques well known to those skilled in the art with dna sequence dna of the present invention or the recombinant vectors transformed host cell that contains described dna sequence dna.When the host was prokaryotic organism such as intestinal bacteria, the competent cell that can absorb DNA can be used CaCl in exponential growth after date results
2Method is handled, and used step is well-known in this area.Alternative is to use MgCl
2If desired, transforming also the method for available electroporation carries out.When the host is an eukaryote, can select following DNA transfection method for use: coprecipitation of calcium phosphate method, perhaps conventional mechanical method such as microinjection, electroporation, liposome packing etc.
By the recombinant DNA technology of routine, utilize polynucleotide sequence of the present invention to can be used to express or produce human II aminoacyl-tRNA synthetase 11 .77 (Science, 1984 of reorganization; 224:1431).In general following steps are arranged:
(1). with the polynucleotide (or varient) of everybody II aminoacyl-tRNA synthetase 11 .77 of coding of the present invention, or transform or the transduction proper host cell with the recombinant expression vector that contains these polynucleotide;
(2). in suitable medium, cultivate host cell;
(3). separation, protein purification from substratum or cell.
In step (2), according to used host cell, used substratum can be selected from various conventional substratum in the cultivation.Under the condition that is suitable for the host cell growth, cultivate.After host cell grows into suitable cell density, induce the promotor of selection with suitable method (as temperature transition or chemical induction), cell is cultivated for some time again.
In step (3), recombinant polypeptide can wrap and be expressed or be secreted into the extracellular in cell or on cytolemma.If desired, can utilize its physics, the separating by various separation methods with other characteristic and the albumen of purification of Recombinant of chemistry.These methods are well-known to those skilled in the art.These methods include, but are not limited to: conventional renaturation is handled, protein precipitant is handled (salt analysis method), centrifugal, the broken bacterium of infiltration, the combination of ultrasonication, super centrifugal, sieve chromatography (gel-filtration), adsorption chromatography, ion exchange chromatography, high performance liquid chromatography (HPLC) and other various liquid chromatography (LC) technology and these methods.
The antagonist of polypeptide of the present invention and this polypeptide, agonist and inhibitor can be directly used in disease treatment, for example, can treat malignant tumour, adrenal gland defect, tetter, all kinds of inflammation, HIV infection and immunological disease etc.
Aminoacyl-tRNA synthetase is vital to proteinic correct synthesizing.Aminoacyl-tRNA synthetase can be used for treatment and prevention because endocrine system, and the not normal and disease that causes of immunity system and nervous function can also be used for treatment and preventing cancer.
Specifically for the present invention, polypeptide of the present invention or its segment can be used for the disease for the treatment of or preventing to cause owing to endocrine system is not normal, include but not limited to: diabetes insipidus, precocious puberty, diabetes, thyroprivia, Adrenal cortex function insufficiency etc.
Polypeptide current segment of the present invention can be used for the disease for the treatment of or preventing to cause owing to immunity system is not normal, includes but not limited to: rheumatoid arthritis, chronic active hepatitis, the primary dry syndrome, acute anterior uveitis, hemochromatosis, systemic lupus erythematous, scleroderma, polymyositis, myasthenia gravis, autoimmune hemolytic anemia, immunologic thrombocytopenic purpura, autoimmunity interstitial nephritis, autoimmunity heart trouble etc.
Polypeptide of the present invention or its segment can also be used to the disease for the treatment of or preventing to cause owing to nervous function is not normal, include but not limited to: myasthenia gravis, spinal muscular atrophy, the false hypertrophy of flesh, myotonic dystrophy, myodystonia, slow dyskinesia etc.
Polypeptide of the present invention or its segment can also be used to treatment or prevent various cancers.Include but not limited to: nasal cavity and tumor of sinus of nose, nasopharyngeal carcinoma, laryngocarcinoma, tracheal neoplasm, lung cancer, mesothelioma of pleura;
Digestive system tumor: salivary gland tumor, the esophageal carcinoma, oesophagus leiomyosarcoma, primary esophageal small cell carcinoma, cancer of the stomach, malignant lymphoma of stomach, carcinoid of stomach, large bowel cancer, colorectal carcinoma, Malignant Lymphoma of Intestinal Tract, primary hepatocarcinoma, hepatoblastoma, primary carcinoma of gallbladder, carcinoma of the pancreas
Blood, lymphsystem tumor: acute leukemia, chronic graininess leukemia, lymphocytic leukemia, malignant lymphoma (as lymphoreticular tissue, malignant lymphoma, hodgkin's lymphoma, non Hodgkin lymphoma etc.), malignant histocytosis
Nervous system neoplasm: astrocytoma, ependymoma, medulloblastoma, meningioma, glioma, acoustic tumor, angiogenic tumour, Pituitaryadenoma, craniopharyngioma
Motor system tumour: osteoid osteoma, osteochondroma, chondroma, osteoblastoma, chondroblastoma etc.), malignant bone tumor such as giant cell tumor of bone, osteosarcoma, chondrosarcoma, ewing's sarcoma, myelomatosis
Urogenital neoplasm: innocent tumour such as renal cortex tubule adenoma, acidophile adenoma, JGCT, polycystic Kidney knurl, spermocytoma, teratoma, ball Leydig's cell tumor, endometrial stroma tumour, hydatidiform mole, ovarian tumor, mammary gland fibroma, malignant tumour such as renal cell carcinoma, sarcoma of kidney sample cancer, nipple sample renal cell carcinoma, the nephroblastoma, prostate cancer, ball tumour choriocarcinoma, attached cancer, cervical cancer, carcinoma of endometrium, uterus choriocarcinoma, defeated flexible pipe cancer, malignant tumor of ovary, mammary cancer
Endocrine system carcinoma: pituitary adenoma, thyroid benign tumour, thyroid carcinoma, parathyroid adenoma, parathyroid carcinoma, suprarenal gland myelolipoma, pheochromocytoma, islet cells tumour, multiple endocrine neoplasm, thymus neoplasms
Soft tissue neoplasm: fibroma, fibrosarcoma, fibromatosis, lipoma, liposarcoma, leiomyoma, leiomyosarcoma, rhabdomyoma, rhabdosarcoma, synovial tissue's knurl, vascular tumor, intramuscular hemangioma, glomus tumor, hemangioendothelial sarcoma, lymphangioma, Lymphangiomyoma, lymphangioendothelial sarcoma, histiocytoma, malignant fibrous histiocytoma, alveolar soft part sarcoma, clear cell sarcoma, myxoma, the outer ewing's sarcoma of bone, the soft tissue osteogenic sarcoma, the soft tissue chondrosarcoma, mesenchymoma, epithelioid sarcoma, schwannoma, neurofibroma, malignant schwannoma, neurofibromatosis
Malignant tumour of skin: skin Mike glucagonoma, Kaposi sarcoma, melanoma
The present invention also provides SCREENED COMPOUND to identify the method that improves (agonist) or check the medicament of (antagonist) human II aminoacyl-tRNA synthetase 11 .77.Agonist improves human II aminoacyl-tRNA synthetase 11 .77 biological function such as stimulate cellular proliferation, and antagonist prevention disorder such as the various cancer relevant with cell hyperproliferation with treatment.For example, can be in the presence of medicine, the human II aminoacyl-tRNA synthetase 11 .77 with mark cultivates with mammalian cell or the film preparation of expressing human II aminoacyl-tRNA synthetase 11 .77.Measure the medicine raising then or check this interactional ability.
The antagonist of human II aminoacyl-tRNA synthetase 11 .77 comprises antibody, compound, acceptor disappearance thing and the analogue etc. that filter out.The antagonist of human II aminoacyl-tRNA synthetase 11 .77 can combine and eliminate its function with human II aminoacyl-tRNA synthetase 11 .77; or suppress the generation of this polypeptide, or combine with the avtive spot of this polypeptide and to make this polypeptide can not bring into play biological function.
In screening during as the compound of antagonist; human II aminoacyl-tRNA synthetase 11 .77 can be added in the bioanalysis mensuration, interactional influence between human II aminoacyl-tRNA synthetase 11 .77 and its acceptor be determined whether compound is antagonist by measuring compound.With the same quadrat method of above-mentioned SCREENED COMPOUND, can filter out the acceptor disappearance thing and the analogue of antagonist action.Can be incorporated into the rondom polypeptide storehouse that solid formation forms by the various amino acid that may make up by screening with human II aminoacyl-tRNA synthetase 11 .77 bonded peptide molecule obtains.During screening, generally tackle human II aminoacyl-tRNA synthetase 11 .77 molecule and carry out mark.
The invention provides and use polypeptide, and fragment, derivative, analogue or their cell are as the method for antigen with production antibody.These antibody can be polyclonal antibody or monoclonal antibody.The present invention also provides the antibody at human II aminoacyl-tRNA synthetase 11 .77 antigenic determinant.These antibody include, but is not limited to: the fragment that polyclonal antibody, monoclonal antibody, chimeric antibody, single-chain antibody, Fab fragment and Fab expression library produce.
The method of the available human II aminoacyl of the production of polyclonal antibody-tRNA synthetase 11 .77 direct injection immune animal (as rabbit, mouse, rat etc.) obtains, and multiple adjuvant can be used for the enhancing immunity reaction, includes but not limited to freund's adjuvant etc.The technology of the monoclonal antibody of preparation human II aminoacyl-tRNA synthetase 11 .77 includes but not limited to hybridoma technology (Kohler and Milstein.Nature; 1975,256:495-497), three knurl technology; people B-quadroma technology, EBV-hybridoma technology etc.With the variable region bonded chimeric antibody in human constant region and inhuman source can with existing technology production (Morrison etal, PNAS, 1985,81:6851).And the technology of existing manufacture order chain antibody (U.S.Pat No.4946778) also can be used for producing the single-chain antibody of anti-human II aminoacyl-tRNA synthetase 11 .77.
The antibody of anti-human II aminoacyl-tRNA synthetase 11 .77 can be used in the immunohistochemistry technology, detects the human II aminoacyl-tRNA synthetase 11 .77 in the biopsy specimen.
With human II aminoacyl-also available labelled with radioisotope of tRNA synthetase 11 .77 bonded monoclonal antibody, inject in the body and can follow the tracks of its position and distribution.This radiolabeled antibody can be used as a kind of atraumatic diagnostic method and is used for the location of tumour cell and has judged whether transfer.
Antibody also can be used for designing the immunotoxin at a certain privileged sites in the body.As the monoclonal antibody of human II aminoacyl-tRNA synthetase 11 .77 high-affinity can with bacterium or plant poison (as diphtheria toxin, ricin, abrine etc.) covalent attachment.A kind of usual method is with sulfydryl linking agent such as SPDP, attacks the amino of antibody, by the exchange of disulfide linkage, toxin is incorporated on the antibody, and this hybrid antibody can be used for killing human II aminoacyl-tRNA synthetase 11 .77 positive cells.
Antibody among the present invention can be used for treating or prevention and disease that human II aminoacyl-tRNA synthetase 11 .77 is relevant.The antibody that gives suitable dosage can stimulate or block generation or the activity of human II aminoacyl-tRNA synthetase 11 .77.
The invention still further relates to the diagnostic testing process of quantitative and detection and localization human II aminoacyl-tRNA synthetase 11 .77 level.These tests are known in the art, and comprise that FISH measures and radioimmunoassay.The human II aminoacyl that is detected in the test-tRNA synthetase 11 .77 level can and be used to diagnose the disease that human II aminoacyl-tRNA synthetase 11 .77 works with the human II aminoacyl that the lays down a definition-importance of tRNA synthetase 11 .77 in various diseases.
Polypeptide of the present invention also can be used as the peptide spectrum analysis, for example, the polypeptide available physical, chemistry or enzyme carry out the specificity cutting, and carries out the two-dimentional or three-dimensional gel electrophoresis analysis of one dimension, be more preferably and carry out mass spectroscopy.
The polynucleotide of coding human II aminoacyl-tRNA synthetase 11 .77 also can be used for multiple therapeutic purpose.Gene therapy technology can be used for treating because cell proliferation, growth or the metabolic disturbance due to the nothing expression of human II aminoacyl-tRNA synthetase 11 .77 or the unusual/non-activity expression.The gene therapy vector (as virus vector) of reorganization can be designed for the human II aminoacyl-tRNA synthetase 11 .77 that expresses variation, to suppress endogenic human II aminoacyl-tRNA synthetase 11 .77 activity.For example, a kind of human II aminoacyl of variation-tRNA synthetase 11 .77 can be the human II aminoacyl-tRNA synthetase 11 .77 that shortens, lacked signal conduction function territory, though can combine with the substrate in downstream, lacks signaling activity.Therefore the gene therapy vector of reorganization can be used for treating the disease of human II aminoacyl-tRNA synthetase 11 .77 expression or active caused by abnormal.Deriving from viral expression vector such as retrovirus, adenovirus, adeno-associated virus (AAV), hsv, parvovirus etc. can be used for the polynucleotide of coding human II aminoacyl-tRNA synthetase 11 .77 are transferred in the cell.The method of recombinant viral vector that structure carries the polynucleotide of coding human II aminoacyl-tRNA synthetase 11 .77 is found in existing document (Sambrook, et al.).Reorganization coding human II aminoacyl-polynucleotide of tRNA synthetase 11 .77 can be packaged in the liposome and be transferred in the cell in addition.
Polynucleotide import tissue or intracellular method comprises: directly be injected into polynucleotide in the in-vivo tissue; Or external by carrier (as virus, phage or plasmid etc.) earlier with the polynucleotide transfered cell in, again cell is transplanted in the body etc.
Suppress the oligonucleotide (comprising sense-rna and DNA) of human II aminoacyl-tRNA synthetase 11 .77 mRNA and ribozyme also within the scope of the invention.Ribozyme is the enzyme sample RNA molecule that a kind of energy specificity is decomposed specific RNA, and its mechanism of action is to carry out the endonuclease effect after ribozyme molecule and the hybridization of complementary target RNA-specific.The RNA of antisense and DNA and ribozyme can obtain with existing any RNA or DNA synthetic technology, as the technology widespread use of solid phase phosphoamide chemical synthesis synthetic oligonucleotide.Antisense rna molecule can be transcribed acquisition by the dna sequence dna of this RNA that encodes in external or body.This dna sequence dna has been incorporated into the downstream of rna polymerase promoter of carrier.In order to increase the stability of nucleic acid molecule, available several different methods is modified it, and as increasing the sequence length of both sides, the connection between the ribonucleoside is used phosphoric acid thioester bond or peptide bond but not phosphodiester bond.
The polynucleotide of coding human II aminoacyl-tRNA synthetase 11 .77 can be used for the diagnosis with the relative disease of human II aminoacyl-tRNA synthetase 11 .77.The unconventionality expression of the expression that the polynucleotide of coding human II aminoacyl-tRNA synthetase 11 .77 can be used for detecting human II aminoacyl-tRNA synthetase 11 .77 human II aminoacyl-tRNA synthetase 11 .77 whether or under morbid state.As the dna sequence dna of the human II aminoacyl of encoding-tRNA synthetase 11 .77 can be used for biopsy specimen is hybridized to judge the expression situation of human II aminoacyl-tRNA synthetase 11 .77.Hybridization technique comprises the Southern blotting, Northern blotting, in situ hybridization etc.These technological methods all are disclosed mature technologies, and relevant test kit all can obtain from commercial channels.Part or all of polynucleotide of the present invention can be used as probe stationary on microarray (Microarray) or DNA chip (being called " gene chip " again), is used for analyzing the differential expression analysis and the gene diagnosis of tissue gene.Carry out the transcription product that RNA-polymerase chain reaction (RT-PCR) amplification in vitro also can detect human II aminoacyl-tRNA synthetase 11 .77 with the special primer of human II aminoacyl-tRNA synthetase 11 .77.
The sudden change that detects human II aminoacyl-tRNA synthetase 11 .77 gene also can be used for the disease of diagnosing human II aminoacyl-tRNA synthetase 11 .77 relevant.The point mutation that form comprises with the normal wild type human II aminoacyl-tRNA synthetase 11 .77 dna sequence dna is compared of human II aminoacyl-tRNA synthetase 11 .77 sudden change, transposition, disappearance, reorganization and other are any unusual etc.Available existing technology such as Southern blotting, dna sequence analysis, PCR and in situ hybridization detect sudden change.In addition, sudden change might influence proteic expression, therefore can judge indirectly that with Northern blotting, Western blotting gene has or not sudden change.
Sequence of the present invention identifies it also is valuable to karyomit(e).This sequence can be specifically at certain bar human chromosome particular location and and can with its hybridization.At present, need to identify the concrete site of each gene on the karyomit(e).Now, have only chromosomal marker thing seldom to can be used for the marker chromosomes position based on actual sequence data (repetition polymorphism).According to the present invention, for these sequences are associated with disease related gene, its important the first step is positioned these dna sequence dnas on the karyomit(e) exactly.
In brief, prepare PCR primer (preferred 15-35bp), sequence can be positioned on the karyomit(e) according to cDNA.Then, these primers are used for the somatocyte hybrid cell that the PCR screening contains each bar human chromosome.Have only those hybrid cells that contain corresponding to the people's gene of primer can produce the fragment of amplification.
The PCR localization method of somatocyte hybrid cell is that DNA is navigated to concrete chromosomal quick method.Use Oligonucleolide primers of the present invention,, can utilize one group to realize inferior location from specific chromosomal fragment or a large amount of genomic clone by similar approach.Other the similar strategy that can be used for chromosomal localization comprises in situ hybridization, uses the karyomit(e) prescreen and the hybridization preliminary election of the airflow classification of mark, thereby makes up the special cDNA storehouse of karyomit(e).
The cDNA clone is carried out fluorescence in situ hybridization (FISH) with Metaphase Chromosome, can in a step, accurately carry out chromosomal localization.The summary of this technology is referring to Verma etc., Human Chromosomes:a Manualof Basic Techniques, Pergamon Press, New York (1988).
In case sequence is positioned to chromosome position accurately, the physical location of this sequence on karyomit(e) just can be associated with the gene map data.These data for example are found in, V.Mckusick, MendelianInheritance in Man (can by with the online acquisition of Johns Hopkins University Welch Medical Library).Can pass through linkage analysis then, determine gene and navigated to relation between the disease on the chromosomal region already.
Then, need to measure ill and not cDNA between diseased individuals or genome sequence difference.If observe certain sudden change in some or all of diseased individuals, and this sudden change is not observed in any normal individual, then this sudden change may be the cause of disease of disease.More ill and diseased individuals not is usually directed at first seek the variation of structure in the karyomit(e), as from the horizontal visible of karyomit(e) or use based on detectable disappearance of the PCR of cDNA sequence or transposition.Resolving power according to present physical mapping and assignment of genes gene mapping technology, being accurately positioned to the cDNA of the chromosomal region relevant with disease, can be a kind of (the supposing that 1 megabasse mapping resolving power and every 20kb are corresponding to a gene) between 50 to 500 potential Disease-causing genes.
Polypeptide of the present invention, polynucleotide and stand-in thereof, agonist, antagonist and inhibitor and suitable pharmaceutical carrier combination back can be used.These carriers can be water, glucose, ethanol, salt, damping fluid, glycerine and their combination.Composition comprises the polypeptide or the antagonist of safe and effective amount and carrier and the vehicle that does not influence effect of drugs.These compositions can be used as medicine and are used for disease treatment.
The present invention also provides medicine box or the test kit that contains one or more containers, and one or more medicinal compositions compositions of the present invention are housed in the container.With these containers, can have by the given indicative prompting of government authorities of making, using or selling medicine or biological products, the government authorities that this prompting reflects production, uses or sells permits it to use on human body.In addition, polypeptide of the present invention can be used in combination with other treatment compound.
Pharmaceutical composition can be with mode administration easily, as by in part, intravenously, intraperitoneal, intramuscular, subcutaneous, the nose or the route of administration of intracutaneous.Human II aminoacyl-tRNA synthetase 11 .77 comes administration with the amount that treats and/or prevents concrete indication effectively.The amount and the dosage range that are applied to human II aminoacyl-tRNA synthetase 11 .77 of patient will depend on many factors, as administering mode, person's to be treated healthiness condition and diagnostician's judgement.
Following accompanying drawing is used to illustrate specific embodiments of the present invention, and is not used in qualification by the scope of the invention that claims defined.
Fig. 1 is the gene chip expression spectral comparison diagram of human II aminoacyl of the present invention-tRNA synthetase 11 .77 and human II aminoacyl-tRNA synthetic enzyme.Last figure is the express spectra folding side figure of human II aminoacyl-tRNA synthetase 11 .77, and the below sequence is the express spectra folding side figure of human II aminoacyl-tRNA synthetic enzyme.Wherein, 1-tire brain, 2-normal brain activity, 3-tire kidney, 4-liver cancer, 5-tire liver, 6-adult liver, 7-Tiroidina, 8-tire lung, 9-lung, 10-muscle, 11-thymus gland, 12-glioma.
Fig. 2 is the polyacrylamide gel electrophoresis figure (SDS-PAGE) of isolating human II aminoacyl-tRNA synthetase 11 .77.11.77kDa be proteinic molecular weight.The arrow indication is isolated protein band.
Below in conjunction with specific embodiment, further set forth the present invention.Should be understood that these embodiment only to be used to the present invention is described and be not used in and limit the scope of the invention.The experimental technique of unreceipted actual conditions in the following example, usually according to people such as normal condition such as Sambrook, molecular cloning: laboratory manual (New York:ColdSpring Harbor Laboratory Press, 1989) condition described in, or the condition of advising according to manufacturer.Embodiment 1: the clone of human II aminoacyl-tRNA synthetase 11 .77
Extract the total RNA of people's tire brain with guanidinium isothiocyanate/phenol/chloroform single stage method.From total RNA, separate poly (A) mRNA with Quik mRNA Isolation Kit (Qiegene company product).2ug poly (A) mRNA forms cDNA through reverse transcription.CDNA fragment orientation is inserted on the multiple clone site of pBSK (+) carrier (Clontech company product) with Smart cDNA clone's test kit (available from Clontech), transforms DH5 α, bacterium forms the cDNA library.Measure all clones' 5 ' and 3 ' terminal sequence with Dyeterminate cycle reaction sequencing kit (Perkin-Elmer company product) and ABI 377 automatic sequencers (Perkin-Elmer company).CDNA sequence and the existing public dna sequence data storehouse (Genebank) measured are compared, found that the cDNA sequence of one of them clone 1157C07 is new DNA.By synthetic a series of primers the contained insertion cDNA fragment of this clone is carried out two-way mensuration.The result shows, the contained full-length cDNA of 1157C07 clone is 2822bp (shown in Seq ID NO:1), from 1070bp to 2543bp the open reading frame (ORF) of a 324bp, the new protein (shown in Seq ID NO:2) of encoding arranged.We are with this clone's called after pBS-1157C07, encoded protein matter called after human II aminoacyl-tRNA synthetase 11 .77.Embodiment 2: with the gene of RT-PCR method clones coding human II aminoacyl-tRNA synthetase 11 .77
Total RNA is a template with fetus brain cell, is that primer carries out the synthetic cDNA of reverse transcription reaction with oligo-dT, with behind the test kit purifying of Qiagene, carries out pcr amplification with following primer:
Primer1：5’-ATACAAAGATTTAACTAGTGTTTC-3’(SEQ?ID?NO：3)
Primer2：5’-CATAGGCCGAGGCGGCCGACATGT-3’(SEQ?ID?NO：4)
Primer1 is the forward sequence that begins of 1bp that is positioned at the 5 ' end of SEQ ID NO:1;
Primer2 be SEQ ID NO:1 in 3 ' end reverse sequence.
The condition of amplified reaction: in the reaction volume of 50 μ l, contain 50mmol/L KCl, 10mmol/L Tris-Cl, (pH8.5), 1.5mmol/L MgCl
2, 200 μ mol/L dNTP, 10pmol primer, the Taq archaeal dna polymerase of 1U (Clontech company product).Go up by 25 cycles of following conditioned response at PE9600 type DNA thermal cycler (Perkin-Elmer company): 94 ℃ of 30sec; 55 ℃ of 30sec; 72 ℃ of 2min.When RT-PCR, establish the blank negative contrast of positive contrast of β-actin and template simultaneously.Amplified production is connected to (Invitrogen company product) on the pCR carrier with the test kit purifying of QIAGEN company with TA clone test kit.The dna sequence analysis result shows that the dna sequence dna of PCR product and the 1-2822bp shown in the SEQ ID NO:1 are identical.Embodiment 3:Northern blotting is analyzed human II aminoacyl-tRNA synthetase 11 .77 expression of gene:
Extract total RNA[Anal.Biochem 1987,162,156-159 with single stage method].This method comprises acid guanidine thiocyanate phenol-chloroform extracting.Promptly use 4M guanidinium isothiocyanate-25mM Trisodium Citrate, 0.2M sodium acetate (pH4.0) carries out homogenate to tissue, adds the phenol of 1 times of volume and the chloroform-primary isoamyl alcohol (49: 1) of 1/5 volume, and is centrifugal after mixing.The sucking-off aqueous phase layer adds Virahol (0.8 volume) and with the centrifugal RNA precipitation that obtains of mixture.With RNA precipitation 70% washing with alcohol that obtains, dry and soluble in water.With 20 μ g RNA, on 1.2% sepharose that contains 20mM 3-(N-morpholino) propanesulfonic acid (pH7.0)-5mM sodium acetate-1mM EDTA-2.2M formaldehyde, carry out electrophoresis.Be transferred on the nitrocellulose filter then.With α-
32P dATP prepares by random priming
32The dna probe of P-mark.Used dna probe is the human II aminoacyl-tRNA synthetase 11 .77 coding region sequence (1070bp to 2543bp) of pcr amplification shown in Figure 1.Probe (about 2 * 10 with the 32P-mark
6Cpm/ml) spend the night in 42 ℃ of hybridization in a solution with the nitrocellulose filter that has shifted RNA, this solution comprises 50% methane amide-25mM KH
2PO
4(pH7.4)-5 * SSC-5 * Denhardt ' s solution and 200 μ g/ml salmon sperm DNAs.After the hybridization, filter membrane is washed 30min in 55 ℃ in 1 * SSC-0.1%SDS.Then, analyze with quantitative with Phosphor Imager.Embodiment 4: vivoexpression, separation and the purifying of reorganization human II aminoacyl-tRNA synthetase 11 .77
According to SEQ ID NO:1 and coding region sequence shown in Figure 1, design a pair of specificity amplification primer, sequence is as follows:
Primer3：5’-CCCCATATGATGCAAAAGCAGTTACAGTATTTC-3’(Seq?ID?No：5)
Primer4：5’-CCCGTCGACCTAGGAAAGACATCCTGCCTTCCA-3’(Seq?ID?No：6)
5 ' end of these two sections primers contains NdeI and SalI restriction enzyme site respectively, be respectively the encoding sequence of target gene 5 ' end and 3 ' end thereafter, NdeI and SalI restriction enzyme site are corresponding to expression vector plasmid pET-28b (+) (Novagen company product, Cat.No.69865.3) the selectivity restriction enzyme site on.With the pBS-1157C07 plasmid that contains the total length goal gene is template, carries out the PCR reaction.The PCR reaction conditions is: contain pBS-1157C07 plasmid 10pg, primer Primer-3 and Primer-4 among the cumulative volume 50 μ l and be respectively 10pmol, Advantage polymerase Mix (Clontech company product) 1 μ l.Loop parameter: 94 ℃ of 20s, 60 ℃ of 30s, 68 ℃ of 2min, totally 25 circulations.Respectively amplified production and plasmid pET-28 (+) are carried out double digestion with NdeI and SalI, reclaim big fragment respectively, and connect with the T4 ligase enzyme.Connect product and transform, after the dull and stereotyped overnight incubation of the LB that contains kantlex (final concentration 30 μ g/ml), use the colony polymerase chain reaction (PCR) method screening positive clone, and check order with the big enterobacterial DH5 of Calcium Chloride Method α.Select the correct positive colony of sequence (pET-1157C07) with Calcium Chloride Method with recombinant plasmid transformed e. coli bl21 (DE3) plySs (Novagen company product).In the LB liquid nutrient medium that contains kantlex (final concentration 30 μ g/ml), host bacterium BL21 (pET-1157C07) is cultured to logarithmic phase at 37 ℃, adds IPTG to final concentration 1mmol/L, continues to cultivate 5 hours.Centrifugal collection thalline; through the broken bacterium of ultrasonic wave; centrifugal collection supernatant; with carrying out chromatography, obtained the target protein human II aminoacyl-tRNA synthetase 11 .77 of purifying with 6 Histidines (6His-Tag) bonded affinity column His.Bind Quick Cartridge (Novagen company product).Through the SDS-PAGE electrophoresis, obtain a single band (Fig. 2) at the 11.77kDa place.This band is transferred on the pvdf membrane carries out the n terminal amino acid sequential analysis with the Edams hydrolysis method, 15 amino acid of N-end hold 15 amino-acid residues identical with the N-shown in the SEQ ID NO:2 as a result.Embodiment 5 anti-human II aminoacyls-tRNA synthetase 11 .77 production of antibodies
Synthesize following human II aminoacyl-specific polypeptide of tRNA synthetase 11 .77 with Peptide synthesizer (PE company product):
NH2-Met-Gln-Lys-Gln-Leu-Gln-Tyr-Phe-Arg-Ser-Trp-Ser-Ser-Leu-Cys-COOH(SEQ?ID?NO：7)。Form compoundly with hemocyanin and bovine serum albumin coupling this polypeptide respectively, method is referring to Avrameas, et al.Immunochemistry, 1969; 6:43.Add the complete Freund's adjuvant immunizing rabbit with the above-mentioned hemocyanin polypeptide complex of 4mg, add the incomplete Freund's adjuvant booster immunization once with the hemocyanin polypeptide complex again after 15 days.Employing is done the titre that ELISA measures antibody in the rabbit anteserum through the titer plate of 15 μ g/ml bovine serum albumin polypeptide complex bag quilts.From the rabbit anteserum of antibody positive, separate total IgG with albumin A-Sepharose.Polypeptide is incorporated on the Sepharose4B post of cyanogen bromide-activated, from total IgG, separates anti-peptide antibody with affinity chromatography.Immuno-precipitation proof antibody purified can combine with human II aminoacyl-tRNA synthetase 11 .77 specifically.Embodiment 6: polynucleotide passage of the present invention is as the application of hybridization probe
Picking out suitable oligonucleotide fragment from polynucleotide of the present invention is of use in many ways as hybridization probe, as can whether containing polynucleotide sequence of the present invention and detect the homologous polynucleotide sequence to identify it with the healthy tissues of different sources or the genome or the hybridization of cDNA library of pathological tissue with this probe, whether further also available this probe in detecting polynucleotide sequence of the present invention or the expression of its homologous polynucleotide sequence in healthy tissues or pathological tissue cell be unusual.
The purpose of present embodiment is to pick out suitable oligonucleotide fragment as hybridization probe from polynucleotide SEQ ID NO:1 of the present invention, and identifies in some tissues whether contain polynucleotide sequence of the present invention or its homologous polynucleotide sequence with the filter hybridization method.The filter hybridization method comprises dot blotting, Southern blotting, Northern blotting and copy method etc., and they all are that polynucleotide sample to be measured is fixed on use essentially identical step crossover in back on the filter membrane.These identical steps are: the filter membrane of having fixed sample at first carries out prehybridization with the hybridization buffer that does not contain probe, so that nonspecific combining site suppressed by vector of sample and synthetic polymer institute are saturated on the filter membrane.Prehybridization solution is contained the hybridization buffer replacement of label probe then, and insulation makes probe and target nucleic acid hybridization.After the hybridization step, the probe in the hybridization is not removed by a series of film steps of washing.Present embodiment utilizes the film condition of washing (as than low salt concn and higher temperature) of higher-strength, so that hybrid context reduces and only keep the signal of high specificity.The probe that present embodiment is selected for use comprises two classes: first kind probe be fully with the identical or complementary oligonucleotide fragment of polynucleotide SEQ ID NO:1 of the present invention; The second class probe is part and the identical or complementary oligonucleotide fragment of polynucleotide SEQ ID NO:1 of the present invention.Present embodiment selects for use dot blotting that sample is fixed on the filter membrane, higher-strength wash under the film condition, the hybridization specificity of first kind probe and sample is the strongest and kept.One, probe selects for use
From polynucleotide SEQ ID NO:1 of the present invention, select oligonucleotide fragment as hybridization probe, the several aspects that should follow following principle and need to consider: 1, the probe size preferable range is a 18-50 Nucleotide; 2, GC content is 30%-70%, and surpassing then, non-specific hybridization increases; 3, probe interior should not have complementary region; 4, what meet above condition can be used as the primary election probe, further do the computer sequential analysis then, comprise this primary election probe is carried out homology relatively with its source sequence area (being SEQ ID NO:1) and other known genome sequence and complementary district thereof respectively, if with the homology in non-target molecule zone greater than 85% or there are 15 continuous bases of surpassing identical, then this primary election probe is general just should not use; 5, whether the primary election probe finally is chosen to be the probe of actual application value also should further be determined by experiment.
Select and synthetic following two probes after finishing the analysis of above each side:
Probe 1 (probe1) belongs to first kind probe, and complete homology of gene fragment or the complementation (41Nt) of SEQ ID NO:1:
5’-TGCAAAAGCAGTTACAGTATTTCCGAAGTTGGAGTTCTCTT-3’(SEQ?ID?NO：8)
Probe 2 (probe2) belongs to the second class probe, is equivalent to gene fragment or its complementary segmental replacement mutant nucleotide sequence (41Nt) of SEQ ID NO:1:
5’-TGCAAAAGCAGTTACAGTATGTCCGAAGTTGGAGTTCTCTT-3’(SEQ?ID?NO：9)
Other unlisted common agents and the compound method thereof relevant with following concrete experimental procedure please refer to document: DNA PROBES G.H.Keller; M.M.Manak; Stockton Press, 1989 (USA) and molecular cloning laboratory manual books more commonly used are as works such as " molecular cloning experiment guide " (second edition in 1998) [U.S.] Sa nurse Brooker, Science Press.
Specimen preparation: 1, from fresh or frozen tissue, extract DNA
Step: 1) the fresh or fresh normal liver tissue that thaws is put into the plate that is immersed on ice and fills phosphate buffered saline buffer (PBS).With scissors or scalpel tissue is cut into small pieces.Should keep organizing moistening in the operation.2) with 1000g centrifugal chopper tissue 10 minutes.3) with cooled homogenate damping fluid (0.25mol/L sucrose; 25mmol/LTris-HCl, pH7.5; 25mmol/LnaCl; 25mmol/L MgCl
2) precipitation that suspends (approximately 10ml/g).4) 4 ℃ with electric homogenizer homogenate tissue suspension at full speed, until tissue by broken fully.5) 1000g is centrifugal 10 minutes.6) with re-suspended cell precipitation (the initial tissue sample of every 0.1g adds 1-5ml), centrifugal 10 minutes again with 1000g.7) with the resuspended precipitation of lysis buffer (the initial tissue sample of every 0.1g adds 1ml), connect following phenol extraction process then.2, the phenol extraction process of DNA
Step: 1) wash cell, centrifugal 10 minutes of 1000g with the cold PBS of 1-10ml.2) with the sedimentary cell (1 * 10 of cold cell pyrolysis liquid resuspension
8The minimum of applications 100ul lysis buffer of cell/ml).3) adding SDS is 1% to final concentration, if before re-suspended cell SDS is directly joined in the cell precipitation, cell may form big agglomerate and be difficult to fragmentation, and the overall yield that reduces.This point is in extracting＞10
7Especially severe during cell.4) add Proteinase K to final concentration 200ug/ml.5) 50 ℃ of insulation reaction 1 hour or 37 ℃ gently jolting spend the night.6) use equal-volume phenol: chloroform: primary isoamyl alcohol (25: 24: 1) extracting, in little centrifuge tube centrifugal 10 minutes.Two corresponding clear separation, otherwise carry out centrifugal again.7) water is transferred to new pipe.8) use the equal-volume chloroform: primary isoamyl alcohol (24: 1) extracting, centrifugal 10 minutes.9) water that will contain DNA is transferred to new pipe.Carry out purifying and the ethanol sedimentation of DNA then.3, the purifying of DNA and ethanol sedimentation
Step: 1) 1/10 volume 2mol/L sodium-acetate and 2 times of cold 100% ethanol of volume are added in the dna solution mixing.-20 ℃ of placements 1 hour or to spending the night.2) centrifugal 10 minutes.3) careful sucking-off or pour out ethanol.4) with 70% cold ethanol 500ul washing precipitation, centrifugal 5 minutes.5) careful sucking-off or pour out ethanol.With the cold washing with alcohol precipitation of 500ul, centrifugal 5 minutes.6) careful sucking-off or pour out ethanol is inverted on thieving paper then residual ethanol is flow to end.Dry air 10-15 minute, so that the volatilization of surperficial ethanol.Note not making the precipitation complete drying, otherwise dissolve again than difficulty.7) with small volume TE or the resuspended DNA precipitation of water.The low speed vortex vibrates or uses the dropper pressure-vaccum, increases TE gradually simultaneously, is mixed to DNA and fully dissolves, every 1-5 * 10
6Cell extracted approximately adds 1ul.
Below the 8-13 step only be used for must removing when depolluting, otherwise can directly carry out the 14th step.8) RNA enzyme A is added in the dna solution, final concentration is 100ug/ml, and 37 ℃ are incubated 30 minutes.9) add SDS and Proteinase K, final concentration is respectively 0.5% and 100ug/ml.37 ℃ are incubated 30 minutes.10) use isopyknic phenol: chloroform: primary isoamyl alcohol (25: 24: 1) extractive reaction liquid, centrifugal 10 minutes.11) carefully shift out water, use isopyknic chloroform: primary isoamyl alcohol (24: 1) extracting again, centrifugal 10 minutes.12) carefully shift out water, add 1/10 volume 2mol/L sodium-acetate and the cold ethanol of 2.5 volumes, mixing put-20 ℃ 1 hour.13) with 70% ethanol and 100% washing with alcohol precipitation, dry air, resuspended nucleic acid, process is with the 3-6 step.14) measure A
260And A
280To detect purity and the productive rate of DNA.15) deposit in-20 ℃ after the packing.The preparation of sample film:
1) get 4 * 2 suitably nitrocellulose filters (NC film) of size, mark point sample position and sample number thereon gently with pencil, each probe needs two NC films, so that wash film with high strength condition and strength condition respectively in the experimental procedure of back.
2) draw and contrast respectively 15 microlitres, put on the sample film, dry at room temperature.
3) place infiltration that 0.1mol/LNaOH is arranged, last 5 minute of filter paper (twice) of 1.5mol/LNaCl, drying to place to soak into has 0.5mol/L Tris-HCl (pH7.0), last 5 minute of filter paper (twice) of 3mol/LNaCl, dries.
4) be sandwiched in the clean filter paper, wrap, 60-80 ℃ of vacuum-drying 2 hours with aluminium foil.
The mark of probe
1) 3 μ lProbe (0.10D/10 μ l) add 2 μ lKinase damping fluids, 8-10uCi γ-
32P-dATP+2UKinase is to add to final volume 20 μ l.
2) 37 ℃ are incubated 2 hours.
3) add the tetrabromophenol sulfonphthalein indicator (BPB) of 1/5 volume.
4) cross Sephadex G-50 post.
5) to having
32Before washing out, P-Probe begins to collect first peak (available Monitor monitoring).
6) 5/pipe, collect the 10-15 pipe.
7) monitor isotopic weight with liquid glimmer instrument
8) merge and to be required preparation behind the collection liquid of first peak
32P-Probe (second peak for free γ-
32P-dATP).
Prehybridization
The sample film is placed plastics bag, and adding 3-10mg prehybridization solution (10 * Denhardt ' s; 6 * SSC, 0.1mg/mlCT DNA (calf thymus DNA).), seal sack after, 68 ℃ of water-baths were shaken 2 hours.
Hybridization
Plastics bag is cut off one jiao, adds the probe prepare, seal sack after, 42 ℃ of water-baths are shaken and are spent the night.
Wash film: high strength is washed film:
1) good sample film has been hybridized in taking-up.
2) 2 * SSC among the 0.1%SDS, washes 15 minutes (2 times) for 40 ℃.
3) 0.1 * SSC among the 0.1%SDS, washes 15 minutes (2 times) for 40 ℃.
4) 0.1 * SSC among the 0.1%SDS, washes 30 minutes (2 times) for 55 ℃, and room temperature is dried.Low strength is washed film:
1) good sample film has been hybridized in taking-up.
2) 2 * SSC among the 0.1%SDS, washes 15 minutes (2 times) for 37 ℃.
3) 0.1 * SSC among the 0.1%SDS, washes 15 minutes (2 times) for 37 ℃.
4) 0.1 * SSC among the 0.1%SDS, washes 15 minutes (2 times) for 40 ℃, and room temperature is dried.
X-light autography:
-70 ℃, X-light autography (the compressing tablet time decides according to hybridization spot radioactivity is strong and weak).
Experimental result:
Adopt low strength to wash the hybrid experiment that the film condition is carried out, more than two strong and weak not obviously differences of probe hybridization spot radioactivity; And adopting high strength to wash the hybrid experiment that the film condition is carried out, the hybridization spot radioactive intensity of probe 1 obviously is better than the radioactive intensity of another probe hybridization spot.Thereby available probe 1 is qualitative and analyze existence and the differential expression of polynucleotide of the present invention in different tissues quantitatively.Embodiment 7 DNA Microarray
Gene chip or gene micromatrix (DNA Microarray) are that present many National Laboratories and big drugmaker are all in the new technology of setting about developing and developing, it is meant and is arranged in a large amount of target fragments on the carriers such as glass, silicon in an orderly manner, to high-density, carry out the comparison and the analysis of data then with fluoroscopic examination and computer software, to reach purpose quick, efficient, that bioinformation is analyzed on high-throughput ground.Polynucleotide of the present invention can be used as target DNA and are used for biochip technology and are used for high-throughput and study new gene function; Seek and the new gene of the screening tissue specificity new gene of disease-related such as tumour particularly; The diagnosis of disease is as heredopathia.The existing in the literature multiple report of its concrete grammar step is as consulting document DeRisi, J.L., Lyer, V.﹠amp; Brown, P.O. (1997) Science278,680-686. and document Helle, R.A., Schema, M., Chai, A., Shalom, D., (1997) PNAS 94:2150-2155.(1) point sample
Various full-length cDNA amounts to 4000 polynucleotide sequences as target DNA, comprising polynucleotide of the present invention.They are increased by PCR respectively, behind the purifying gained amplified production its concentration is transferred to about 500ng/ul, (available from U.S. Cartesian company) puts on glass medium with Cartesian 7500 point sample instruments, and distance between points is 280 μ m.Slide behind the point sample is carried out hydration, drying, places UV-crosslinked instrument crosslinked, and the wash-out after drying is fixed on DNA and is prepared into chip on the sheet glass.The existing in the literature multiple report of its concrete grammar step, the point sample post-processing step of present embodiment is:
1. hydration 4 hours in the wet environment;
2.0.2%SDS washed 1 minute;
3.ddH
2The O washed twice, each 1 minute;
4.NaBH
4Sealed 5 minutes;
5.95 in ℃ water 2 minutes;
6.0.2%SDS washed 1 minute;
7.ddH
2Twice of O flushing;
8. airing, 25 ℃ to be stored in the dark place standby.(2) probe mark
With the single stage method total mRNA of extracting from human body mixed structure and body particular organization (or through stimulated cells strain) respectively, and with Oligotex mRNA Midi Kit (available from QiaGen company) purified mRNA, by reverse transcription respectively with fluorescent reagent Cy3dUTP (5-Amino-propargyl-2 '-deoxyuridine 5 '-triphatecoupled to Cy3 fluorescent dye, available from Amersham Phamacia Biotech company) mRNA of mark human body mixed structure, with fluorescent reagent Cy5dUTP (5-Amino-propargyl-2 '-deoxyuridine5 '-triphate coupled to Cy5 fluorescent dye, available from Amersham Phamacia Biotech company) mRNA of mark body particular organization (or through stimulated cells strain), prepare probe after purified.Concrete steps reference and method are seen: Schena, M., Shalon, D., Heller, R. (1996) Proc.Natl.Acad.Sci.USA.Vol.93:10614-10619.Schena, M., Shalon, Dari., Davis, R.W. (1995) Science.270. (20): 467-480. (three) hybridization
Respectively will be from the probe of above two kinds of tissues with chip at UniHyb
TMHybridized 16 hours in HybridizationSolution (available from the TeleChem company) hybridization solution, room temperature washings (1 * SSC, 0.2%SDS) the washing back is scanned with ScanArray 3000 scanners (available from U.S. General Scanning company), the image of scanning carries out data analysis with Imagene software (U.S. Biodiscovery company) to be handled, and calculates the Cy3/Cy5 ratio of each point.
Be respectively normal brain activity, liver cancer, muscle, tire brain, tire kidney, tire lung, tire liver, Tiroidina, thymus gland, adult liver, lung, glioma with upper machine body particular organization (or through stimulated cells strain).Draw folding side figure according to these 18 Cy3/Cy5 ratios.(Fig. 1).Human II aminoacyl of the present invention as seen from the figure-tRNA synthetase 11 .77 is very similar with human II aminoacyl-tRNA synthetic enzyme express spectra.
Sequence table (1) general information:
(ii) denomination of invention: human II aminoacyl-tRNA synthetase 11 .77 and encoding sequence thereof
(iii) sequence number: the information of 9 (2) SEQ ID NO:1:
(i) sequence signature:
(A) length: 2822bp
(B) type: nucleic acid
(C) chain: two strands
(D) topological framework: linearity
(ii) molecule type: cDNA
( xi ) ：SEQ ID NO：1： 1 ATACAAAGATTTAACTAGTGTTTCTGGGTTGGATTTTTGAAATAGTATGCAAGTCATAAG 61 CACAGTTTCAATAAAACACGTATTCTGGAGGTGCGTGGAACTTTGTATTATTTGTAGTTG121 AGAAAGGCAAACTTTGCTGACAAACCAGTACCTATCACAAACGAACACAAAAAGTAGCTG181 TTACTGTGCAGGCTGTCTTTAACTTTCATTTCATAAAGGGTACATTATTGTTAAACTCTA241 CTACATGGTTTGGGGAGAAATCCAGTGGTTTTATTTAAATGAACACTCTCACACTGCCTT301 TTGATCAACTTTCAAAGTATTTTGCAGATGCATTTTGAGCATGACCATTTTTTTCCCCAA361 GTAAAAACAATTGTGCGTGGCCTCCATATAACTCAGAAAGCATGCTCTTACTACCTATGC421 AAGCAAACAATAAAACATATAGACATGAAATGTTAAGTCTTAAAAAAAAAAGGCAACAAT481 TATGGAGCTCTATTTTTAAATTTGTGATTTTCAAAATATGGCTTACTCATCATTGTGTAG541 AAGAGCATGAATGCGATTTCTTGTTTTGCTCTGCATATATTTCTCTGCTGTTTTTCTGAT601 CATTGGCGAGATTGTAAAGTATTTTGCAAGCAGAAGTGGAATTGGATATGTTGAACACAC661 ATCATTGGTGTACATACTGTATTTAGCCTGAAGACTTTCCTAAAGTGTTTTGTTCTAAAA721 ATAACCTGCCATTTTCTATAGATTTTAATTTTTTATATCTTCAAGGGTTCTATTTTGGTC781 ACAAGGAAAGAATGTGGCTTCTAATAGTGCTAAGAATTAAAAGATGCTTTTATAGAGACT841 TAGAGCTATTTTGAAAAGCTTTGGGGCTTCCCAGCCACTGATCACAATTAGACTAAGCCC901 ATGGAATTTCTGGGAGTGTTGTGCAGTGGATTCGGTTCTAGATCCATCTTACATTTGTTT 961 AGTGTTTCCCAATTTTTGGGAGAAGGGGTGCACAGCAAATTTGAGAGACTTTTTTGAATC1021 TCACACATGTATTTTCCTCAAGATTCTTTTAAGCCTCTTCTGAATGACTTGTCTGAGATA1081 GTGAAGACCCACATTAACTAGAATCAGCTGGGGAACTTTAAAAAATACAGTGCCTGGGTC1141 CCAGTCCCTAGCTTTTGATCTAATTCATGTAGGGGTGGGATCCAGGAATTACCATGTATT1201 TTAAAAGCTTCTGGGTGTTTCTAATTTGCAGACAGATTGAGAACCACTATGATACGTCAT1261 CCCTTTACTGAGAATTATGGCGAGAATCACTGCCATTTGAATTACTCAGGAGTGACTGAT1321 TCCTCAGTTGTGTAGGAGAAGCAGAAAAAATAAGAATAAAAAGAATTGAGAGATACTGAT1381 ATCAAACTCCCATTTGAAATACAAGGGCCCTTCTGATTCAAGGCCCAGTTGGGGAGCTTG1441 GACCATGTTGTGAATGGCCTAGCACTCGCCAGTCTGGTGGAAATTGGTGGTCTTAGTTGC1501 TGGAGCAGGCTGAGTGTCCCCGCGGGGTTTGCATCTGTCCCCAGAACCTTTTCCCCAGGC1561 CCGTGGGGGAATAGGGAAGTCACTCTGAGCTAGAAATTGTCGAAGAAGAAAAGAAACAAC1621 CTTCCTAGCCTTGGAAAGCCTGTCCCTGCTTTTGATAGAATTATTGCCTTTTTGTAGGAA1681 TTACAGTAGCAAACCCCAGGCTGCCGCTGAATTTCCTACTTTTGCTCATTCTCTAGGATA1741 GTTCTTATCCAGAATGTGGTTTCAGGAATTCTTTTTTTTAGTTTGAAAATGAATGTGAAA1801 CATTTTCTTTGGTGTCTTTTTTTTTAAAAAAAAAAAACCCTTATTGCTATTTTTTCGTGT1861 TTTTGTTTTGTTTTGTTTTTTGTTTGTTTTACCATTAAGTAATACACATCCCAGAATTTG1921 GCACTCTGTGTTAACTGTGGAGGCAAATAAAATTTAGTTTTAATCTGTGGTGAGCTGAAT1981 GCACTACAACACCTTCGAAGTAATCTGATGGTTTCATTCTGTCGAGCCTCATGCTGCCTA2041 CAAAACACCACAATTTACCTGGTGTTTTCAACATTTTAAGGAATGAAGATACAAGTAGAC2101 ATGCAAGTTGGAAATGTTTCTTTAGAAAGGCCATCCAGAATAATGATATCTGTTGCAGTC2161 GTCCAAATGCAATATGAAATTTCCTAGGTGCTATTATAAACGGTGTGGTGTCATACCAAA2221 TGCAAAAGCAGTTACAGTATTTCCGAAGTTGGAGTTCTCTTTGTAGGCCTTTCAAATACG2281 TGTTTGCATTCCATAGAGGTCTGCTCACCAACTGTGCCTCTCACCACTGGTTAAAATTGA2341 ATTTAAGCCTCATTGACATAAGTCGTTTCTTGATTGAACTCTTCAGTTTTTACACTGGAA2401 TTTCTGTAGTTGTCTTGAAAGCTGCATGTCACATCACTGTACACAAAGTGCTTTGGTATT2461 ACTCATGCACCGTGGATAGTGATTTCTGTGTCGTTTTCATTTTCAGTTGTACAGTAATAT2521 GGAAGGCAGGATGTCTTTCCTAGAGGCTGGAAGAAAAGTGTATCGTACATTTTAAATTTA2581 TTTTAGAACAAGTGCATGAGATGTGTCACTGATTTCTGTTATTTATTTGTATGTTTTATT2641 ATTCAAAGTGTATGCACTTTTAAGAAGCAGAATTTATATTTTTACGTTTGAAACATTTTA2701 TTTCTGAAACAGCGTTGATTATATAGTATACAGTTGGAATTAAGAGAAAAGTGGAAAATG2761 TAACAAAATCCAATAAATTTATTACAAAAAAAAAAAAAACATGTCGGCCGCCTCGGCCTA2821 TG ( 3 ) SEQ ID NO：2：
(i) sequence signature:
(A) length: 107 amino acid
(B) type: amino acid
(D) topological framework: linearity
(ii) molecule type: polypeptide
(xi) sequence description: the information of SEQ ID NO:2:1 Met Gln Lys Gln Leu Gln Tyr Phe Arg Ser Trp Ser Ser Leu Cys 16 Arg Pro Phe Lys Tyr Val Phe Ala Phe His Arg Gly Leu Leu Thr 31 Asn Cys Ala Ser His His Trp Leu Lys Leu Asn Leu Ser Leu Ile 46 Asp Ile Ser Arg Phe Leu Ile Glu Leu Phe Ser Phe Tyr Thr Gly 61 Ile Ser Val Val Val Leu Lys Ala Ala Cys His Ile Thr Val His 76 Lys Val Leu Trp Tyr Tyr Ser Cys Thr Val Asp Ser Asp Phe Cys 91 Val Val Phe Ile Phe Ser Cys Thr Val Ile Trp Lys Ala Gly Cys106 Leu Ser (4) SEQ ID NO:3
(i) sequence signature
(A) length: 24 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity
(ii) molecule type: oligonucleotide
(xi) sequence description: the information of SEQ ID NO:3:ATACAAAGATTTAACTAGTGTTTC 24 (5) SEQ ID NO:4
(i) sequence signature
(A) length: 24 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity
(ii) molecule type: oligonucleotide
(xi) sequence description: the information of SEQ ID NO:4:CATAGGCCGAGGCGGCCGACATGT 24 (6) SEQ ID NO:5
(i) sequence signature
(A) length: 33 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity
(ii) molecule type: oligonucleotide (xi) sequence description: the information of SEQ ID NO:5:CCCCATATGATGCAAAAGCAGTTACAGTATTTC 33 (7) SEQ ID NO:6
(i) sequence signature
(A) length: 33 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity
(ii) molecule type: oligonucleotide (xi) sequence description: the information of SEQ ID NO:6:CCCGTCGACCTAGGAAAGACATCCTGCCTTCCA 33 (8) SEQ ID NO:7:
(i) sequence signature:
(A) length: 15 amino acid
(B) type: amino acid
(D) topological framework: linearity
(ii) molecule type: polypeptide (xi) sequence description: the information of SEQ ID NO:7:Met-Gln-Lys-Gln-Leu-Gln-Tyr-Phe-Arg-Ser-Trp-Ser-Ser-Leu-Cys 15 (9) SEQ ID NO:8
(i) sequence signature
(A) length: 41 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity
(ii) molecule type: oligonucleotide (xi) sequence description: the information of SEQ ID NO:8:TGCAAAAGCAGTTACAGTATTTCCGAAGTTGGAGTTCTCTT 41 (10) SEQ ID NO:9
(i) sequence signature
(A) length: 41 bases
(B) type: nucleic acid
(C) chain: strand
(D) topological framework: linearity
(ii) molecule type: oligonucleotide (xi) sequence description: SEQ ID NO:9:TGCAAAAGCAGTTACAGTATGTCCGAAGTTGGAGTTCTCTT 41
Claims (18)
1, a kind of isolated polypeptide-human II aminoacyl-tRNA synthetase 11 .77 is characterized in that it includes: the polypeptide of the aminoacid sequence shown in the SEQ ID NO:2 or active fragments, analogue or the derivative of its polypeptide.
2, polypeptide as claimed in claim 1, the aminoacid sequence that it is characterized in that described polypeptide, analogue or derivative has the homogeny with the aminoacid sequence at least 95% shown in the SEQ ID NO:2.
3, polypeptide as claimed in claim 2 is characterized in that it comprises the polypeptide with the aminoacid sequence shown in the SEQ ID NO:2.
4, a kind of isolating polynucleotide, it is characterized in that described polynucleotide comprise be selected from down the group in a kind of:
(a) coding have aminoacid sequence shown in the SEQ ID NO:2 polypeptide or its fragment, analogue, derive
The polynucleotide of thing;
(b) with polynucleotide (a) complementary polynucleotide; Or
(c) with (a) or the polynucleotide of at least 70% homogeny (b) are arranged.
5, polynucleotide as claimed in claim 4 is characterized in that described polynucleotide comprise the polynucleotide that coding has aminoacid sequence shown in the SEQID NO:2.
6, polynucleotide as claimed in claim 4, the sequence that it is characterized in that described polynucleotide include the sequence of 1-2822 position among the sequence of 1070-2543 position among the SEQ IDNO:1 or the SEQ ID NO:1.
7, a kind of recombinant vectors that contains exogenous polynucleotide is characterized in that it is the recombinant vectors that is formed by the described polynucleotide of arbitrary claim among the claim 4-6 and plasmid, virus or vehicle expression vector establishment.
8, a kind of genetically engineered host cell that contains exogenous polynucleotide is characterized in that it is to be selected from following a kind of host cell:
(a) host cell that transforms or transduce with the described recombinant vectors of claim 7; Or
(b) host cell that transforms or transduce with the described polynucleotide of the arbitrary claim among the claim 4-6.
9, a kind of preparation method with human II aminoacyl-active polypeptide of tRNA synthetase 11 .77 is characterized in that described method comprises:
(a) expressing under human II aminoacyl-tRNA synthetase 11 .77 condition, cultivate the described through engineering approaches host cell of claim 8;
(b) from culture, isolate and have human II aminoacyl-the active polypeptide of tRNA synthetase 11 .77.
10, a kind of can with polypeptide bonded antibody, it is characterized in that described antibody be can with human II aminoacyl-tRNA synthetase 11 .77 specificity bonded antibody.
11, the compound of an analoglike or adjusting polypeptide active or expression is characterized in that they are simulation, promotion, antagonism or the active compound that suppresses human II aminoacyl-tRNA synthetase 11 .77.
12, compound as claimed in claim 11 is characterized in that it is the polynucleotide sequence shown in the SEQ ID NO:1 or its segmental antisense sequences.
13, the described application of compound of a kind of claim 11, it is characterized in that described compound be used to regulate human II aminoacyl-tRNA synthetase 11 .77 in vivo, the method for external activity.
14, a kind of disease relevant or method of disease susceptibility of detecting with the described polypeptide of arbitrary claim among the claim 1-3, it is characterized in that it comprises the described polypeptide expression amount that detects, perhaps detect the activity of described polypeptide, perhaps detect and cause described expression of polypeptides amount or active unusual nucleotide diversity in the polynucleotide.
15, as the application of polypeptide as described in the arbitrary claim among the claim 1-3, it is characterized in that it is applied to screen stand-in, the agonist of human II aminoacyl-tRNA synthetase 11 .77, antagonist or inhibitor; Perhaps be used for the peptide finger print identification.
16, as the application of the described nucleic acid molecule of arbitrary claim among the claim 4-6, it is characterized in that it is used for nucleic acid amplification reaction as primer, perhaps be used for hybridization, perhaps be used to make gene chip or microarray as probe.
17,, it is characterized in that forming pharmaceutical composition with safe and effective dosage and pharmaceutically acceptable carrier as diagnosis or the treatment disease relevant unusually with human II aminoacyl-tRNA synthetase 11 .77 with described polypeptide, polynucleotide or its stand-in, agonist, antagonist or inhibitor as the described polypeptide of arbitrary claim, polynucleotide or application of compound in claim 1-6 and 11.
18, the described polypeptide of arbitrary claim, polynucleotide or the application of compound among the claim 1-6 and 11, it is characterized in that being used for the treatment of as malignant tumour with described polypeptide, polynucleotide or compound, hemopathy, the medicine of HIV infection and immunological disease and all kinds of inflammation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00127268 CN1352252A (en) | 2000-11-06 | 2000-11-06 | New polypeptide-human II aminoacyl-tRNA synthetase 11.77 and polynucleotide for encoding such polypeptide |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00127268 CN1352252A (en) | 2000-11-06 | 2000-11-06 | New polypeptide-human II aminoacyl-tRNA synthetase 11.77 and polynucleotide for encoding such polypeptide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1352252A true CN1352252A (en) | 2002-06-05 |
Family
ID=4592286
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 00127268 Pending CN1352252A (en) | 2000-11-06 | 2000-11-06 | New polypeptide-human II aminoacyl-tRNA synthetase 11.77 and polynucleotide for encoding such polypeptide |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1352252A (en) |
Cited By (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011072266A3 (en) * | 2009-12-11 | 2011-11-03 | Atyr Pharma, Inc. | Aminoacyl trna synthetases for modulating hematopoiesis |
| US8404242B2 (en) | 2009-03-16 | 2013-03-26 | Atyr Pharma, Inc. | Compositions and methods comprising histidyl-tRNA synthetase splice variants having non-canonical biological activities |
| US8404471B2 (en) | 2008-06-26 | 2013-03-26 | Atyr Pharma, Inc. | Compositions and methods comprising glycyl-tRNA synthetases having non-canonical biological activities |
| US8828395B2 (en) | 2009-12-11 | 2014-09-09 | Atyr Pharma, Inc. | Antibodies that bind tyrosyl-tRNA synthetases |
| US8835387B2 (en) | 2012-02-16 | 2014-09-16 | Atyr Pharma, Inc. | Histidyl-tRNA synthetases for treating autoimmune and inflammatory diseases |
| US8945541B2 (en) | 2010-05-14 | 2015-02-03 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-tRNA synthetases |
| US8946157B2 (en) | 2010-05-03 | 2015-02-03 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of seryl-tRNA synthetases |
| US8961960B2 (en) | 2010-04-27 | 2015-02-24 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases |
| US8961961B2 (en) | 2010-05-03 | 2015-02-24 | a Tyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of arginyl-tRNA synthetases |
| US8962560B2 (en) | 2010-06-01 | 2015-02-24 | Atyr Pharma Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Lysyl-tRNA synthetases |
| US8969301B2 (en) | 2010-07-12 | 2015-03-03 | Atyr Pharma Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-tRNA synthetases |
| US8980253B2 (en) | 2010-04-26 | 2015-03-17 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase |
| US8981045B2 (en) | 2010-05-03 | 2015-03-17 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-tRNA synthetases |
| US8986681B2 (en) | 2010-04-27 | 2015-03-24 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of threonyl-tRNA synthetases |
| US8986680B2 (en) | 2010-04-29 | 2015-03-24 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases |
| US8993723B2 (en) | 2010-04-28 | 2015-03-31 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl-tRNA synthetases |
| US8999321B2 (en) | 2010-07-12 | 2015-04-07 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases |
| US9029506B2 (en) | 2010-08-25 | 2015-05-12 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-tRNA synthetases |
| US9034321B2 (en) | 2010-05-03 | 2015-05-19 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases |
| US9034320B2 (en) | 2010-04-29 | 2015-05-19 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Valyl-tRNA synthetases |
| US9034598B2 (en) | 2010-05-17 | 2015-05-19 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-tRNA synthetases |
| US9062301B2 (en) | 2010-05-04 | 2015-06-23 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutamyl-prolyl-tRNA synthetases |
| US9062302B2 (en) | 2010-05-04 | 2015-06-23 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-tRNA synthetase complex |
| US9068177B2 (en) | 2010-04-29 | 2015-06-30 | Atyr Pharma, Inc | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases |
| US9127268B2 (en) | 2009-12-11 | 2015-09-08 | Atyr Pharma, Inc. | Aminoacyl tRNA synthetases for modulating inflammation |
| US9399770B2 (en) | 2010-10-06 | 2016-07-26 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tryptophanyl-tRNA synthetases |
| US9422539B2 (en) | 2010-07-12 | 2016-08-23 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-tRNA synthetases |
| US9453214B2 (en) | 2009-02-27 | 2016-09-27 | Atyr Pharma, Inc. | Polypeptide structural motifs associated with cell signaling activity |
| US9499810B2 (en) | 2008-06-11 | 2016-11-22 | Atyr Pharma, Inc. | Thrombopoietic activity of tyrosyl-tRNA synthetase polypeptides |
| US9587235B2 (en) | 2013-03-15 | 2017-03-07 | Atyr Pharma, Inc. | Histidyl-tRNA synthetase-Fc conjugates |
| US9688978B2 (en) | 2011-12-29 | 2017-06-27 | Atyr Pharma, Inc. | Aspartyl-tRNA synthetase-Fc conjugates |
| US9714419B2 (en) | 2011-08-09 | 2017-07-25 | Atyr Pharma, Inc. | PEGylated tyrosyl-tRNA synthetase polypeptides |
| US9796972B2 (en) | 2010-07-12 | 2017-10-24 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases |
| US9816084B2 (en) | 2011-12-06 | 2017-11-14 | Atyr Pharma, Inc. | Aspartyl-tRNA synthetases |
| US9822353B2 (en) | 2011-12-06 | 2017-11-21 | Atyr Pharma, Inc. | PEGylated aspartyl-tRNA synthetase polypeptides |
| US9896680B2 (en) | 2009-03-31 | 2018-02-20 | Atyr Pharma, Inc. | Compositions and methods comprising aspartyl-tRNA synthetases having non-canonical biological activities |
| US11767520B2 (en) | 2017-04-20 | 2023-09-26 | Atyr Pharma, Inc. | Compositions and methods for treating lung inflammation |
-
2000
- 2000-11-06 CN CN 00127268 patent/CN1352252A/en active Pending
Cited By (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9499810B2 (en) | 2008-06-11 | 2016-11-22 | Atyr Pharma, Inc. | Thrombopoietic activity of tyrosyl-tRNA synthetase polypeptides |
| US9157076B2 (en) | 2008-06-26 | 2015-10-13 | Atyr Pharma, Inc. | Compositions and methods comprising glycyl-tRNA synthetases having non-canonical biological activities |
| US8404471B2 (en) | 2008-06-26 | 2013-03-26 | Atyr Pharma, Inc. | Compositions and methods comprising glycyl-tRNA synthetases having non-canonical biological activities |
| US8747840B2 (en) | 2008-06-26 | 2014-06-10 | Atyr Pharma, Inc. | Compositions and methods comprising glycyl-tRNA synthetases having non-canonical biological activities |
| US9585946B2 (en) | 2008-06-26 | 2017-03-07 | Atyr Pharma, Inc. | Compositions and methods comprising glycyl-tRNA synthetases having non-canonical biological activities |
| US9453214B2 (en) | 2009-02-27 | 2016-09-27 | Atyr Pharma, Inc. | Polypeptide structural motifs associated with cell signaling activity |
| US10941214B2 (en) | 2009-03-16 | 2021-03-09 | Atyr Pharma, Inc. | Compositions and methods comprising histidyl-tRNA synthetase splice variants having non-canonical biological activities |
| US10526419B2 (en) | 2009-03-16 | 2020-01-07 | Atyr Pharma, Inc. | Compositions and methods comprising histidyl-tRNA synthetase splice variants having non-canonical biological activities |
| US10017582B2 (en) | 2009-03-16 | 2018-07-10 | Atyr Pharma, Inc. | Compositions and methods comprising histidyl-trna synthetase splice variants having non-canonical biological activities |
| US9605265B2 (en) | 2009-03-16 | 2017-03-28 | Atyr Pharma, Inc. | Compositions and methods comprising histidyl-tRNA synthetase splice variants having non-canonical biological activities |
| US11078299B2 (en) | 2009-03-16 | 2021-08-03 | Atyr Pharma, Inc. | Compositions and methods comprising histidyl-tRNA synthetase splice variants having non-canonical biological activities |
| US8753638B2 (en) | 2009-03-16 | 2014-06-17 | Atyr Pharma, Inc. | Compositions and methods comprising histidyl-TRNA synthetase splice variants having non-canonical biological activities |
| US8404242B2 (en) | 2009-03-16 | 2013-03-26 | Atyr Pharma, Inc. | Compositions and methods comprising histidyl-tRNA synthetase splice variants having non-canonical biological activities |
| US9896680B2 (en) | 2009-03-31 | 2018-02-20 | Atyr Pharma, Inc. | Compositions and methods comprising aspartyl-tRNA synthetases having non-canonical biological activities |
| US9943577B2 (en) | 2009-12-11 | 2018-04-17 | Atyr Pharma, Inc. | Aminoacyl tRNA synthetases for modulating inflammation |
| US9540628B2 (en) | 2009-12-11 | 2017-01-10 | Atyr Pharma, Inc. | Aminoacyl tRNA synthetases for modulating inflammation |
| US8828395B2 (en) | 2009-12-11 | 2014-09-09 | Atyr Pharma, Inc. | Antibodies that bind tyrosyl-tRNA synthetases |
| US9328340B2 (en) | 2009-12-11 | 2016-05-03 | Atyr Pharma, Inc. | Amino acyl tRNA synthetases for modulating inflammation |
| WO2011072266A3 (en) * | 2009-12-11 | 2011-11-03 | Atyr Pharma, Inc. | Aminoacyl trna synthetases for modulating hematopoiesis |
| US9127268B2 (en) | 2009-12-11 | 2015-09-08 | Atyr Pharma, Inc. | Aminoacyl tRNA synthetases for modulating inflammation |
| US10030077B2 (en) | 2010-04-26 | 2018-07-24 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase |
| US9540629B2 (en) | 2010-04-26 | 2017-01-10 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Cysteinyl-tRNA synthetase |
| US10717786B2 (en) | 2010-04-26 | 2020-07-21 | aTye Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Cysteinyl-tRNA synthetase |
| US8980253B2 (en) | 2010-04-26 | 2015-03-17 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase |
| US8986681B2 (en) | 2010-04-27 | 2015-03-24 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of threonyl-tRNA synthetases |
| US9580706B2 (en) | 2010-04-27 | 2017-02-28 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of threonyl-tRNA synthetases |
| US10150958B2 (en) | 2010-04-27 | 2018-12-11 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of threonyl-tRNA synthetases |
| US9528103B2 (en) | 2010-04-27 | 2016-12-27 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases |
| US8961960B2 (en) | 2010-04-27 | 2015-02-24 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases |
| US9896515B2 (en) | 2010-04-27 | 2018-02-20 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases |
| US10563192B2 (en) | 2010-04-27 | 2020-02-18 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of threonyl-tRNA synthetases |
| US9320782B2 (en) | 2010-04-28 | 2016-04-26 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl tRNA synthetases |
| US8993723B2 (en) | 2010-04-28 | 2015-03-31 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl-tRNA synthetases |
| US9623093B2 (en) | 2010-04-29 | 2017-04-18 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl tRNA synthetases |
| US9034320B2 (en) | 2010-04-29 | 2015-05-19 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Valyl-tRNA synthetases |
| US9068177B2 (en) | 2010-04-29 | 2015-06-30 | Atyr Pharma, Inc | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases |
| US9556425B2 (en) | 2010-04-29 | 2017-01-31 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Valyl-tRNA synthetases |
| US8986680B2 (en) | 2010-04-29 | 2015-03-24 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases |
| US10189911B2 (en) | 2010-04-29 | 2019-01-29 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Valyl-tRNA synthetases |
| US9593323B2 (en) | 2010-05-03 | 2017-03-14 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases |
| US9593322B2 (en) | 2010-05-03 | 2017-03-14 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases |
| US9034321B2 (en) | 2010-05-03 | 2015-05-19 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases |
| US8946157B2 (en) | 2010-05-03 | 2015-02-03 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of seryl-tRNA synthetases |
| US9422538B2 (en) | 2010-05-03 | 2016-08-23 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-tRNA synthetasis |
| US8961961B2 (en) | 2010-05-03 | 2015-02-24 | a Tyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of arginyl-tRNA synthetases |
| US8981045B2 (en) | 2010-05-03 | 2015-03-17 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-tRNA synthetases |
| US10179906B2 (en) | 2010-05-03 | 2019-01-15 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases |
| US9340780B2 (en) | 2010-05-03 | 2016-05-17 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of seryl-tRNA synthetases |
| US9574187B2 (en) | 2010-05-04 | 2017-02-21 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutamyl-prolyl-tRNA synthetases |
| US10160814B2 (en) | 2010-05-04 | 2018-12-25 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutamyl-prolyl-tRNA synthetases |
| US9062301B2 (en) | 2010-05-04 | 2015-06-23 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutamyl-prolyl-tRNA synthetases |
| US9062302B2 (en) | 2010-05-04 | 2015-06-23 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-tRNA synthetase complex |
| US9404104B2 (en) | 2010-05-04 | 2016-08-02 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of P38 multi-tRNA synthetase complex |
| US10220080B2 (en) | 2010-05-14 | 2019-03-05 | aTyr Pharam, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-tRNA synthetases |
| US9687533B2 (en) | 2010-05-14 | 2017-06-27 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-tRNA synthetases |
| US8945541B2 (en) | 2010-05-14 | 2015-02-03 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-tRNA synthetases |
| US10179908B2 (en) | 2010-05-17 | 2019-01-15 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-tRNA synthetases |
| US9790482B2 (en) | 2010-05-17 | 2017-10-17 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-tRNA synthetases |
| US9034598B2 (en) | 2010-05-17 | 2015-05-19 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-tRNA synthetases |
| US9347053B2 (en) | 2010-05-27 | 2016-05-24 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases |
| US9322009B2 (en) | 2010-06-01 | 2016-04-26 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Lysyl-tRNA synthetases |
| US8962560B2 (en) | 2010-06-01 | 2015-02-24 | Atyr Pharma Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Lysyl-tRNA synthetases |
| US9315794B2 (en) | 2010-07-12 | 2016-04-19 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-tRNA synthetases |
| US8999321B2 (en) | 2010-07-12 | 2015-04-07 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases |
| US10669533B2 (en) | 2010-07-12 | 2020-06-02 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Histidyl-tRNA synthetases |
| US9796972B2 (en) | 2010-07-12 | 2017-10-24 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases |
| US8969301B2 (en) | 2010-07-12 | 2015-03-03 | Atyr Pharma Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-tRNA synthetases |
| US9637730B2 (en) | 2010-07-12 | 2017-05-02 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-tRNA synthetases |
| US9422539B2 (en) | 2010-07-12 | 2016-08-23 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-tRNA synthetases |
| US10196629B2 (en) | 2010-07-12 | 2019-02-05 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases |
| US10196628B2 (en) | 2010-07-12 | 2019-02-05 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-tRNA synthetases |
| US9428743B2 (en) | 2010-08-25 | 2016-08-30 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-trna synthetases |
| US9029506B2 (en) | 2010-08-25 | 2015-05-12 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-tRNA synthetases |
| US9399770B2 (en) | 2010-10-06 | 2016-07-26 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tryptophanyl-tRNA synthetases |
| US10563191B2 (en) | 2010-10-06 | 2020-02-18 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of tryptophanyl tRNA synthetases |
| US9714419B2 (en) | 2011-08-09 | 2017-07-25 | Atyr Pharma, Inc. | PEGylated tyrosyl-tRNA synthetase polypeptides |
| US9816084B2 (en) | 2011-12-06 | 2017-11-14 | Atyr Pharma, Inc. | Aspartyl-tRNA synthetases |
| US9822353B2 (en) | 2011-12-06 | 2017-11-21 | Atyr Pharma, Inc. | PEGylated aspartyl-tRNA synthetase polypeptides |
| US9688978B2 (en) | 2011-12-29 | 2017-06-27 | Atyr Pharma, Inc. | Aspartyl-tRNA synthetase-Fc conjugates |
| US9273302B2 (en) | 2012-02-16 | 2016-03-01 | Atyr Pharma, Inc. | Histidyl-tRNA synthetases for treating autoimmune and inflammatory diseases |
| US8835387B2 (en) | 2012-02-16 | 2014-09-16 | Atyr Pharma, Inc. | Histidyl-tRNA synthetases for treating autoimmune and inflammatory diseases |
| US10472618B2 (en) | 2013-03-15 | 2019-11-12 | Atyr Pharma, Inc. | Histidyl-tRNA synthetase-Fc conjugates |
| US9587235B2 (en) | 2013-03-15 | 2017-03-07 | Atyr Pharma, Inc. | Histidyl-tRNA synthetase-Fc conjugates |
| US10093915B2 (en) | 2013-03-15 | 2018-10-09 | Atyr Pharma Inc. | Histidyl-tRNA synthetase-Fc conjugates |
| US10711260B2 (en) | 2013-03-15 | 2020-07-14 | Atyr Pharma, Inc. | Histidyl-tRNA synthetase-Fc conjugates |
| US11072787B2 (en) | 2013-03-15 | 2021-07-27 | Atyr Pharma Inc. | Histidyl-tRNA synthetase-Fc conjugates |
| US11767520B2 (en) | 2017-04-20 | 2023-09-26 | Atyr Pharma, Inc. | Compositions and methods for treating lung inflammation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1352252A (en) | New polypeptide-human II aminoacyl-tRNA synthetase 11.77 and polynucleotide for encoding such polypeptide | |
| CN1322818A (en) | New polypeptide human class-II aminoacyl-tRNA synthetase 10 and encoding polynucleotide of the same polypeptide | |
| CN1311300A (en) | New polypeptide-human threonine-tRNA synthetase 14 and polynucleotide for coding such polypeptide | |
| CN1314486A (en) | New polypeptide-human histidinacyl-tRNA sythetase 85 and polynucleotide for coding such polypeptide | |
| CN1298000A (en) | Human class-II amino acyl-tRNA synthetase 9 as one new kind of polypeptide and polynucleotides encoding this polypeptide | |
| CN1361248A (en) | New polypeptide human serine-tRNA synthetase 56.65 and polynucleotides encoding this polypeptide | |
| CN1352248A (en) | New polypeptide-S-adenosylmethionine synthetase 14.08 and polynucleotide for encoding such polypeptide | |
| CN1331243A (en) | Polypeptide-human myoglobulin IXA 11.88 and polynucleotide for coding it | |
| CN1331332A (en) | Polypeptide-human dihydropyrimidinase associated protein-1 (DRP-1) 9.35 and polynucleotide for coding it | |
| CN1331191A (en) | Polypeptide-human myoglobulin IXA14.08 and polynucleotide for coding it | |
| CN1315512A (en) | Polypeptide-human class-II aminoacyl-tRNA synthetase 15 and polynucleotide for coding it | |
| CN1352111A (en) | New polypeptide-human branched chain alpha-keto acid dehydrogenase (BCKDH) E1-beta subunit 11 and polynucleotide for encoding such polypeptide | |
| CN1324929A (en) | New polypeptide human class-II aminoacyl-tRNA synthetase 17 and polynucleotides for encoding same | |
| CN1363579A (en) | Polypeptide-human transcription repressor CCCTC-binding factor 9.68 and polynucleotide for coding it | |
| CN1352153A (en) | New polypeptide-human repressor 11.66 and polynucleotide for encoding such polypeptide | |
| CN1359942A (en) | Polypeptide-human macroprotein 10.01 and polynucleotide for coding it | |
| CN1364888A (en) | New polypeptide-human uracil phosphoribosyl transferase 9.35 and polynucleotide for encoding such polypeptide | |
| CN1363595A (en) | Polypeptide-human signal protein-14.52 and polynucleotide for coding it | |
| CN1352109A (en) | New polypeptide-human transformer-2-beta protein 21.89 and polynucleotide for encoding such polypeptide | |
| CN1351062A (en) | Polypeptide-ribosomal protein L299.13 and polynucleotide for coding it | |
| CN1363657A (en) | Polypeptide-human RNA polymerase I-40KD subunit 10.01 and polynucleotide for coding it | |
| CN1359944A (en) | Polypeptide-human membrane-bound protein 11.99 and polynucleotide for coding it | |
| CN1364793A (en) | New polypeptide-human EF-chiral calcium binding protein 46.42 and polynucleotide for encoding such polypeptide | |
| CN1345757A (en) | Novel polypeptide-ribosomal protein L3235.2 and polynucleotide for encoding said polypeptide | |
| CN1363655A (en) | Polypeptide-human RNA polymerase I-40 KD subunit 9.68 and polynuceotide for coding it |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |